



# LUND UNIVERSITY

## Lipoprotein-associated phospholipase A2 (Lp-PLA2) Impact and role as cardiovascular risk marker

Persson, Margaretha

2008

[Link to publication](#)

### *Citation for published version (APA):*

Persson, M. (2008). *Lipoprotein-associated phospholipase A2 (Lp-PLA2) Impact and role as cardiovascular risk marker*. [Doctoral Thesis (compilation), Department of Clinical Sciences, Malmö]. Department of Clinical Sciences, Lund University.

### *Total number of authors:*

1

### **General rights**

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00

Department of Clinical Sciences in Malmö

Cardiovascular Epidemiology and Internal Medicine Research Groups

Malmö University Hospital

Lund University, Sweden

# Lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>)

Impact and role as cardiovascular risk marker

**Margaretha Persson BSc, RN**



**LUND**  
UNIVERSITY

Faculty of Medicine

Malmö 2008

Cover image with courtesy from diaDexus

Margaretha Persson

Clinical Research Unit, Medicine

Department of Clinical Science in Malmö

Malmö University Hospital, 205 02 Malmö, Sweden

E-mail: [margaretha.persson@med.lu.se](mailto:margaretha.persson@med.lu.se)

Printed by MediaTryck, Lund, Sweden 2008

ISSN 1652-8220

ISBN 978-91-86059-52-1

Department of Clinical Sciences in Malmö  
Cardiovascular Epidemiology and Internal Medicine Research Groups  
Malmö University Hospital  
Lund University, Sweden

## **Lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>)**

Impact and role as cardiovascular risk marker

Margaretha Persson BSc, RN



**LUND**  
UNIVERSITY

Doctoral Dissertation

Akademisk avhandling som, med vederbörligt tillstånd av Medicinska fakulteten vid Lunds Universitet för avläggande av doktorsexamen i medicinsk vetenskap, kommer att offentligen försvaras i aulan, medicinska kliniken, ingång 35, Universitetssjukhuset MAS, Malmö, lördagen den 25 oktober 2008 kl. 09.15

Fakultetsopponent: Professor Olle Wiklund, Göteborgs Universitet

Handledare: Professor Bo Hedblad

## Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA<sub>2</sub>) is today considered a novel specific vascular inflammatory biomarker. The general aim of this thesis was to study the role and impact of Lp-PLA<sub>2</sub> as cardiovascular (CV) risk marker in an epidemiologic perspective. Specific aims were to explore the cross-sectional association of Lp-PLA<sub>2</sub> with traditional CV risk factors, to assess the genetic influence of PLA2G7 on plasma levels of Lp-PLA<sub>2</sub>, and to study the morbidity and mortality of cardiovascular disease (CVD) in relation to Lp-PLA<sub>2</sub>. Data from the population-based “Malmö Diet and Cancer” CV cohort (n=6103) was used. Information on Lp-PLA<sub>2</sub> was available on 5393 subjects (41 % men) with a mean follow-up of 10.6 years. National and local registers were used to retrieve the incidence of coronary events (CE), ischemic stroke and mortality.

Lp-PLA<sub>2</sub> (assessed as activity or mass) increases with age, is higher in males and in current smokers. Lp-PLA<sub>2</sub> is strongly correlated with blood lipids (especially LDL-cholesterol), however, is weakly correlated to glucose and to the extent of carotid asymptomatic atherosclerosis (i.e. intima-media thickness and plaque).

Genetic variation at the PLA2G7 gene locus significantly influences plasma Lp-PLA<sub>2</sub> activity and mass levels, in a position and sex-specific manner.

Both elevated levels of Lp-PLA<sub>2</sub> activity and mass, respectively, are independent of blood lipids, hs-CRP and other traditional cardiovascular risk factors, associated with an increased risk for incident ischemic stroke. No similar independent relationship was observed between Lp-PLA<sub>2</sub> and CE.

Lp-PLA<sub>2</sub> activity, compared with mass, is more strongly correlated to all five components constituting the metabolic syndrome (MetS) and increased more linearly with number of MetS components. Elevated levels of Lp-PLA<sub>2</sub> activity was related to increased risk for incident CVD regardless of MetS. High Lp-PLA<sub>2</sub> levels and presence of MetS were additive predictors of those who experienced a CV event.

It is concluded that both genetic and life-style factors are related to elevated levels of Lp-PLA<sub>2</sub>. Lp-PLA<sub>2</sub> is independently associated with increased CVD risk, in particular ischemic stroke. There is an additive effect of Lp-PLA<sub>2</sub> to presence of MetS on incident CVD risk, which may identify an especially high risk individual.

Till alla dom som hjälpte mig att göra det möjligt!

Var dig själv. Alla andra är redan upptagna.

*Oscar Wilde*

# Contents

Abstract.....	4
Contents.....	7
List of publications.....	9
Abbreviations .....	10
Introduction .....	12
<i>Cardiovascular disease is still a challenge</i> .....	12
<i>Atherosclerosis</i> .....	14
<i>Pathophysiology of Lp-PLA<sub>2</sub> and mechanism of action</i> .....	16
<i>Epidemiologic evidence of Lp-PLA<sub>2</sub> as cardiovascular risk marker</i> .....	18
<i>The Metabolic Syndrome</i> .....	19
<i>Lp-PLA<sub>2</sub> and genetic influences</i> .....	21
Aims of the thesis .....	22
Material and Methods.....	23
<i>Subjects</i> .....	23
<i>Flow chart of study population</i> .....	24
<i>Methods</i> .....	25
<i>Laboratory analyses</i> .....	26
<i>Genetic analyses</i> .....	27
<i>Measurement of Lp-PLA<sub>2</sub> activity and mass</i> .....	28
<i>Definition of the Metabolic Syndrome</i> .....	30
<i>Classification of cardiovascular events</i> .....	31



<i>Statistics</i> .....	32
Results and manuscript specific conclusion.....	35
<i>Paper I</i> .....	35
<i>Paper II</i> .....	38
<i>Paper III</i> .....	40
<i>Paper IV</i> .....	43
General discussion.....	45
<i>Correlation with other cardiovascular risk factors</i> .....	45
<i>Association between Lp-PLA<sub>2</sub> and cardiovascular events</i> .....	51
<i>Clinical implication</i> .....	55
<i>Methodological aspects</i> .....	60
Conclusion.....	62
Summary in Swedish (Populärvetenskaplig sammanfattning) .....	63
Acknowledgements .....	67
References .....	69
Appendix .....	81
Paper I	
Paper II	
Paper III	
Paper IV	

## List of publications

- I. **Persson M**, Nilsson JÅ, Nelson JJ, Hedblad B, Berglund G. The epidemiology of Lp-PLA<sub>2</sub>: Distribution and correlation with cardiovascular risk factors in a population-based cohort. *Atherosclerosis* 2007;190:388-396.
- II. **Persson M**, Nelson JJ, Berglund G, Hedblad B. Lp-PLA<sub>2</sub> activity and mass are associated with increased incidence of ischemic stroke. A population-based cohort study from Malmö, Sweden. *Atherosclerosis* 2008;200:191-198.
- III. **Persson M**, Nelson JJ, Hedblad B, Berglund G. Elevated Lp-PLA<sub>2</sub> levels add prognostic information to the Metabolic Syndrome on Incidence of Cardiovascular Events among middle-aged non-diabetic subjects. *Arterioscler Thromb Vasc Biol.* 2007; 27:1411-1416.
- IV. **Persson M**, Stirnadel H, Carlsson J, Melander O, Berglund G, Hedblad B. In a population-based cohort study; variations in the PLA2G7 gene are associated with Lp-PLA<sub>2</sub> activity and mass. Submitted Manuscript.

Paper I and II, were reproduced according to a general permission from Elsevier Science, Oxford, UK.

Paper III was reproduced with permission from Lippincott Williams & Wilkins.

Illustrations (i.e. Figure 1-2 in Introduction and Figure 1 in Discussion) were printed with permission from Lippincott Williams & Wilkins and Elsevier Science.

## Abbreviations

apo	apolipoprotein
ARIC	Atherosclerosis Risk in Communities Study
ATPIII	Adult Treatment Programme III
BMI	body mass index
CAD	coronary artery disease
CI	confidence interval
CE	coronary events
CHD	coronary heart disease
CV	cardiovascular
CVD	cardiovascular disease
DNA	deoxyribonucleic acid
FDA	Food and Drug Administration
HbA <sub>1</sub> C	Haemoglobin A1C
HDL	high density lipoprotein cholesterol
HOMA	Homeostasis Model Assessment
HRT	hormone replacement treatment
hsCRP	high sensitive C-reactive protein
ICD	International Classification of Diseases
IMT	intima-media thickness
LDL	low-density lipoprotein cholesterol
Lp-PLA <sub>2</sub>	lipoprotein-associated phospholipase A2
Lyso-PC	lyso-phosphatidylcholine
MDCS	Malmö Diet and Cancer Study
MetS	Metabolic syndrome

MI	myocardial infarction
NCEP	National Cholesterol Education Programme
oxFFA	oxidized free fatty acid
oxLDL	oxidized low density lipoprotein cholesterol
PROVE IT TIMI 22	PRavastatin Or atorVastatin Evaluation and Infection Therapy- Thrombosis In Myocardial Infarction Trial
ROC	receiver operator characteristic
RR	relative risk
SD	standard deviation
sdLDL	small-dense LDL
SNP	single nucleotide polymorphism
SPSS	Statistical Package for Social Sciences
STROMA	Stroke registry of Malmö
T2DM	Type 2 diabetes mellitus
US	United States
VA-HIT	Veteran Affairs HDL Intervention Trial
WHS	Women Health Study
WOSCOP	West of Scotland Coronary Prevention Study

# Introduction

## Cardiovascular disease still a challenge

Although mortality from cardiovascular disease (CVD) has decreased markedly over the last decades<sup>1</sup> coronary heart disease (CHD) and stroke still remain the leading cause of death in developed countries<sup>2,3</sup>. CVD accounts for nearly half of all deaths in developed countries<sup>2</sup> and CVD are expected to be the leading cause of death worldwide<sup>4</sup>. About 50% of all CHD and strokes in the population occurs among individuals with normal cholesterol levels<sup>5-7</sup>.

Although the importance of conventional risk factors such as smoking, diabetes, hypertension, and hypercholesterolemia for CVD is clearly documented, a large proportion (62%) of subjects with established coronary artery disease (CAD) do have none or only one of these risk factors<sup>8</sup>. It has been suggested that even after accounting for established risk factors, one-half of all coronary events remains unexplained<sup>9,10</sup>.

Throughout the world, stroke is the second-leading cause of death<sup>11</sup> and in United States (US) as well as in Sweden the third most common cause of death<sup>3,12</sup>. Stroke is also the leading cause of adult disability, and women are at higher risk of stroke than men<sup>13</sup>. Almost 85-90% of all strokes are of ischemic origin<sup>13,14</sup>.

The CVD risk factors that have been targeted most aggressively over the last decades are elevated blood pressure and cholesterol, particularly low-density lipoprotein (LDL)-cholesterol<sup>4</sup>. It is well-documented that lowering LDL-cholesterol with statins reduces the likelihood of CVD for patients at various levels of risk<sup>15-19</sup>. A decreased prevalence of smoking together with an aggressive pharmacological treatment of blood lipids and blood pressure during the last decades has been associated with a decreasing incidence of CVD. However due to a growing aging population CVD will still remain as the leading cause of


premature death<sup>2</sup>. Some authors suggest that LDL-cholesterol is less predictive of CHD than in earlier trials<sup>20</sup>. Even if target LDL-cholesterol goal is achieved there remains a significant residual risk for CHD events<sup>20</sup>. Although elevated levels of LDL-cholesterol contribute to the acceleration of atherosclerosis, it provides little information about the state of the artery wall. In a clinical trial, including post acute syndrome patients, almost every fifth patient had a recurrent cardiovascular event within 2 years despite an aggressive lipid-lowering statin therapy that was associated with markedly reduced LDL-cholesterol level<sup>21</sup>. Furthermore, the initial presentation of CAD has been reported to be myocardial infarction (MI) or sudden cardiac death among 62% men and 42 % among women<sup>22</sup>. Thus, it has been argued that we do need better and more effective tools for identification of persons at high cardiovascular risk<sup>23</sup>.

Risk factors for stroke include age, gender, ethnicity, hypertension, history of CAD or atrial fibrillation, diabetes mellitus, metabolic syndrome (MetS), smoking, alcohol, physical inactivity, etc<sup>24</sup>. The predictive value of blood lipids for incident stroke has been questioned. In the population-based Atherosclerosis Risk in Community (ARIC) study, including almost 13,000 subjects, aged 45-64 years, LDL-cholesterol levels were found to be similar between stroke cases and controls<sup>25</sup>. Furthermore, several clinical trials have shown the reduction in stroke in association with statin therapy<sup>17, 26, 27</sup>. The mechanism is not clearly demonstrated and it has been speculated whether stroke reduction observed in these trials might be explained by statin pleiotropic anti-inflammatory actions<sup>28</sup>. However, recently high levels of apolipoprotein (apo)-B, and low levels of apoA-1 have been reported to be related to increased risk of ischemic stroke<sup>29, 30</sup>.

Today it is widely recommended to use CVD risk assessment tools to identify subjects who should be targeted for intervention. Additional information, beyond traditional CV risk factors, from cardiovascular imaging techniques and biomarkers has been discussed to enhance CAD and stroke risk prediction and possibly the adequacy of risk factor modification.

www.theholisticcare.com

## Atherosclerosis



## Atherosclerosis

The role of atherosclerosis has resulted in a paradigm shift; it is now recognised as a consequence of inflammatory processes and not only an accumulation of lipids in the artery wall. Atherosclerosis is today widely considered as a chronic inflammatory process, with evidence of inflammation at all stages of disease, from initial plaque formation to destabilisation and subsequent rupture<sup>31-33</sup>.

Vascular inflammation starts with an endothelial dysfunction and migration of leukocytes and LDL-cholesterol. When the LDL particle enter the intimal space it may be oxidized, induces the expression of adhesion molecules on endothelial cells, which allows monocyte-derived macrophages and T-lymphocytes to gather in the subendothelial space. These macrophages

have a high affinity for oxidized LDL (oxLDL), and the ingestion of oxLDL particles by macrophages results in the formation of foam cells. The foam cells progress to fatty streaks and atherosclerotic plaques. If excess influx of lipids into the subendothelial space exists the atherosclerotic process proceeds and results in a necrotic lipid rich plaque covered by a fibrous cap. A thin fibrous cap can easily rupture and expose the thrombogenic core to the blood stream with subsequent thrombosis or occlusion of the artery<sup>31</sup>. Many patients suffer from ischemic heart disease despite treatment with lipid-lowering drugs and with LDL-cholesterol levels below target value<sup>7</sup>.

Mechanistic studies have identified blood borne inflammatory cells (e.g monocytes, macrophages, T-lymphocytes) and their products as primary drivers of the inflammatory process<sup>34-36</sup>. Today there is much evidence supporting their role for inflammation in all phases of atherosclerosis<sup>34</sup>. There is documentation that inflammation markers are associated to development of traditional CV risk factors and atherosclerosis<sup>34, 37, 38</sup>.

Several population-based studies were initiated to examine the relation between various inflammatory cells, mediators, markers and incident CVD<sup>10, 35, 39-41</sup>. One inflammatory marker, high sensitivity C-reactive protein (hs-CRP), an acute-phase reactant that reflects low-grade systemic inflammation, has been studied in a variety of cohorts and CVD complications. There are numerous prospective studies providing consistent results of the relationship between elevated baseline levels of hsCRP and increased risk of CVD<sup>42</sup>. In patients with acute coronary syndrome hsCRP has been demonstrated to be associated with increased long-term mortality and coronary heart failure<sup>43</sup>.

It has been stated that a biomarker of atherosclerosis should be directly involved in the causal pathway of plaque formation and inflammation and been shown to have high specificity and low biologic variability<sup>44, 45</sup>. Most markers reflecting a systemic inflammation (i.e. acute




phase reactants as hsCRP) are depending on the presence of infections, rheumatologic disorders, obesity, etc. Furthermore, hsCRP has been shown to have a great biologic fluctuation within an individual and thus questionable for repeated measurements over time due to its high variability. Another emerging inflammatory biomarker with a vascular specificity is lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>). This biomarker has been considered relative unique in its high specificity for and part of a causal pathway of plaque inflammation<sup>46</sup>. This together with a low biologic variability of Lp-PLA<sub>2</sub> has led to the suggestion that Lp-PLA<sub>2</sub> could be a promising biomarker for atherosclerosis<sup>47-49</sup>.

### **Pathophysiology of Lp-PLA<sub>2</sub> and mechanism of action**

Lp-PLA<sub>2</sub> and its role as a novel biomarker for atherosclerosis and vascular inflammation have been explored for several years. Lp-PLA<sub>2</sub>, a 45.4 kDa protein, is a calcium-independent member of the phospholipase A<sub>2</sub> family. Monocytes, macrophages, T-lymphocytes, mast and liver cells are the main sources producing the enzyme Lp-PLA<sub>2</sub><sup>50-52</sup> and these cells are involved in the atherogenesis and progression of atherosclerosis<sup>53</sup>. In humans, Lp-PLA<sub>2</sub> is bound predominantly to LDL-cholesterol and to minor extent to high-density lipoprotein (HDL) cholesterol and very low-density lipoprotein cholesterol<sup>54,55</sup>. Oxidative modification to the phospholipids component of LDL particle provides the substrate for the enzyme<sup>56,57</sup>. When phospholipids are oxidized on the LDL particle, Lp-PLA<sub>2</sub> acts rapidly by cleaving one of the fatty acids on the *sn*-2 position of the glycerol moiety and generates two potent mediators, lysophosphatidylcholine (lyso-PC) and oxidized free fatty acid (oxFFA)<sup>58,53</sup> (Figure 1).


Figure 1.



Lp-PLA<sub>2</sub> acts only on oxLDL and hydrolysis can be carried out solely by Lp-PLA<sub>2</sub><sup>53, 56, 58</sup>. Both the substrate for Lp-PLA<sub>2</sub>, oxLDL and the product lysoPC, have been associated with pro-apoptotic effects on macrophages<sup>58, 59</sup>. Lyso-PC and oxFFA are highly soluble, diffuse throughout the atheroma, and effect the various cell types involved in atherosclerosis<sup>56</sup>. Lyso-PC is a potent chemoattractant for monocytes and T-cells promote endothelial dysfunction, stimulate macrophages proliferation and induce apoptosis in smooth muscle cells<sup>56, 60, 61</sup>. Activated macrophages and foam cells produce more Lp-PLA<sub>2</sub> and Lp-PLA<sub>2</sub> is released by plaques into the circulation<sup>62</sup>. As Lp-PLA<sub>2</sub> is produced within the atherosclerotic plaque, Lp-PLA<sub>2</sub> is more likely to reflect vascular instead of systemic inflammation<sup>63</sup>. LysoPC plays an important role in the effect of Lp-PLA<sub>2</sub> on endothelial dysfunction<sup>62, 64</sup> (Figure 2). In plaques, Lp-PLA<sub>2</sub> was expressed mainly in the necrotic core and surrounding vulnerable and ruptured plaques and to a minor extent in less advanced lesions<sup>65</sup> which suggest that Lp-PLA<sub>2</sub> could be a mediator of plaque progression. An inflammatory process in association with atherosclerosis may take place locally in the vessel wall, however reflected by increased levels of inflammatory biomarkers in the systemic circulation<sup>66</sup>. It has been shown that the expression of Lp-PLA<sub>2</sub> is increased in human aortic atherosclerotic plaques<sup>67</sup>.

Lp-PLA<sub>2</sub> is more expressed in macrophages of vulnerable and ruptured plaques, and within the necrotic core, compared to less advanced plaques<sup>65</sup>.

Figure 2.



### **Epidemiologic evidence of Lp-PLA<sub>2</sub> as a cardiovascular risk marker**

The association between Lp-PLA<sub>2</sub> and CVD has been studied in clinical settings, clinical trials as well as in cohort studies<sup>68-72</sup>. Recently it was shown that Lp-PLA<sub>2</sub> was associated with coronary endothelial dysfunction independently of other CV risk factors<sup>73</sup>. In that study patients with elevated levels of Lp-PLA<sub>2</sub> had an odds ratio (OR) of 3.3 for having coronary endothelial dysfunction compared with patients with normal Lp-PLA<sub>2</sub> levels. In year 2000, a case-control study in association with the West of Scotland Coronary Prevention Study (WOSCOPS) demonstrated that high levels of Lp-PLA<sub>2</sub> were associated with a two-fold increased risk of CHD. This relationship remained after taking traditional CV risk factors and other inflammatory markers (including hsCRP) into account<sup>68</sup>. This finding has been

supported by many population-based studies<sup>70-72</sup> including only healthy individuals. On the contrary, one study, including only women, did however not show the independent association of Lp-PLA<sub>2</sub> with incident CVD<sup>69</sup>. In addition, many clinical epidemiological studies, including patients with established CAD and stroke, has shown the independent association of increased Lp-PLA<sub>2</sub> levels with recurrent CHD and ischemic stroke<sup>74-78</sup>. Assessment of Lp-PLA<sub>2</sub>, in terms of activity and mass, are different in most previous studies. None of these previous studies included simultaneously both Lp-PLA<sub>2</sub> activity and mass assessment within the same study population. Furthermore, some studies included only men or women<sup>72</sup> or only the determination of Lp-PLA<sub>2</sub> mass<sup>68</sup>.




### **Metabolic Syndrome (MetS)**

The MetS is a clustering of metabolic risk factors which increase the risk of developing type 2 diabetes mellitus (T2DM) and CVD<sup>79, 80</sup>. The syndrome has been known since the beginning of 1920 but it was not until 1988 when Gerald Reaven showed an interest in the syndrome and showed its link to insulin resistance<sup>81, 82</sup> that the scientific interest was growing. Today there are several definitions used to define MetS and there is a debate regarding which components should be included<sup>83</sup>. Essential components of MetS are abdominal obesity, elevated blood

pressure, dyslipidemia and glucose intolerance. The World Health Organization (WHO), European Group for the Study of Insulin Resistance (EGIR), the National Cholesterol Education Program (NCEP)/Adult Treatment Panel III (ATPIII), American Association of Clinical Endocrinologists, and International Diabetes Federation (IDF) have all offered somewhat different definitions regarding risk factors and cut-off levels of included components<sup>84</sup>. Nevertheless, all definitions are predictors of CVD but recently reports have indicated a leading role for the ATPIII definition<sup>80, 85-87</sup>.

With an increasing prevalence of MetS and obesity in the general population<sup>88-90</sup> there is an emerging public health problem. Subjects with MetS have higher oxLDL concentrations and more small sized LDL-particles (sdLDL)<sup>91</sup>. Inflammation markers, in particular hsCRP, have also been linked to MetS<sup>92</sup>, and consequently put individuals with MetS at higher risk for CVD. Lp-PLA<sub>2</sub> activity has been shown correlated to sdLDL,<sup>93</sup> to systolic blood pressure, HDL-cholesterol and triglycerides<sup>68,70,72</sup>, i.e. all components constituting the MetS. These correlations could be of interest to explore in the association between MetS and Lp-PLA<sub>2</sub>. In addition, in a study of almost 80 healthy women there was no relationship between Lp-PLA<sub>2</sub> mass levels and insulin resistance as assessed by the insulin suppression test<sup>94</sup>. Individuals with MetS are demonstrated to progress towards diabetes<sup>95</sup> and considered to be at moderate to high risk for CVD<sup>89,90</sup>. Thus, the inclusion of inflammatory biomarkers (i.e. hsCRP or Lp-PLA<sub>2</sub>) could be of clinical importance when assessing cardiovascular risk prediction in patients with MetS<sup>45</sup>.



### **Lp-PLA<sub>2</sub> and genetic influences**

The gene for Lp-PLA<sub>2</sub> (*PLA2G7*) has 12 exons and is located on chromosome 6p21.2 to 12. A large number of single nucleotide polymorphisms (SNPs) have been described, many in small studies, and some variants noted mainly in certain ethnic groups. The most frequently studied SNPs are R92H (rs1805017), I198T (rs1805018), V279P and A379V (rs1051931)<sup>96,97</sup>. The V279P variant is common in Japanese and Turks but absent in Caucasians<sup>98,99</sup>. The missense polymorphisms I198T and A379V, identified mainly in Caucasians, are thought to decrease the substrate affinity of Lp-PLA<sub>2</sub>, possibly prolonging the activity of platelet activating factor, which in turn is associated with many inflammatory diseases<sup>97</sup>. Furthermore, the most studied polymorphism A379V has shown to be associated with higher levels of Lp-PLA<sub>2</sub> activity and lower risk of MI in two European studies<sup>100,101</sup>. On the contrary, in a Taiwanese study the V allele polymorphism in A379V was associated with lower Lp-PLA<sub>2</sub> activity and more complex coronary atherosclerosis<sup>102</sup>. Several other polymorphisms have been identified, but however, so far little is known about their role in affecting the regulation or production of Lp-PLA<sub>2</sub> assessed as activity and mass, respectively.

## **Aims of the thesis**

The general aim of this thesis was to study the role and impact of Lp-PLA<sub>2</sub> as a CV risk marker using a population-based cohort study.

### **Specific aims**

- To explore the effect of genetic variation in *PLA2G7* gene on plasma Lp-PLA<sub>2</sub> activity and mass levels.
- To examine the cross-sectional associations of demographic and anthropometric characteristics and other CVD risk factors with plasma levels of Lp-PLA<sub>2</sub> activity and mass, respectively.
- To explore whether Lp-PLA<sub>2</sub> activity and mass, respectively, are associated with incidence of CHD or ischemic stroke, respectively.
- To study the relationship between Lp-PLA<sub>2</sub> and MetS and to assess the independent contribution of MetS and Lp-PLA<sub>2</sub> on incident CVD.


## Material and methods

### Subjects

The Malmö Diet and Cancer Study (MDCS) is a population-based prospective cohort study designed to explore the associations between dietary habits and cancer<sup>103</sup>. All men, aged 49-73 years, and women, aged 45-73 years, living in the city of Malmö, Sweden were eligible for the study. The only exclusion criteria were mental incapacity or inadequate language skills in Swedish. Recruitment was performed by public advertisement with posters and pamphlets<sup>104</sup>. Participation was voluntary and without any financial compensation. In all 28,449 individuals were enrolled and the participation rate was 41%. Detailed information on non-participants has been presented previously<sup>105</sup>. At baseline examination, each subject was seen by a nurse for anthropometrics, supine blood pressure measurement, non-fasting blood sampling and administration of a questionnaire including hereditary, medical condition, dietary, and life style factors<sup>106</sup>. Between October 1991 and February 1994, every other subject was randomly invited to take part in a sub-study of the epidemiology of the carotid artery disease<sup>106-109</sup> hereto known as the “Cardiovascular cohort”. This cohort consisted of 6,103 subjects (60% women) aged between 46-69 years (mean 58 years). In all subjects included in the cardiovascular cohort a B-mode ultrasound examination of the right carotid artery was performed<sup>108</sup>. Fasting blood samples were not collected at the baseline visit due to logistic reasons. Thus, participants were asked to return for a subsequent visit (median time of 8.6 months after the baseline visit) to donate whole blood samples in a fasting condition. A total of 5,540 of the 6,103 subjects returned and plasma for analysis of lipids and glucose was obtained as well as plasma for storage at minus 80 degree<sup>109</sup>. Of these participants sufficient stores of plasma were available from 5,393 for the purpose of measuring Lp-PLA<sub>2</sub> activity and mass.



## Flowchart of study population in each substudy on Lp-PLA<sub>2</sub>



## Methods

All subjects were seen by a nurse for standardized anthropometric and supine blood pressure measurement. Weight was measured to the nearest 0.1 kilogram using balance-beam scale wearing light in-door clothing and without shoes. Height was measured in standing position to the nearest 1 centimetre and without shoes. Body mass index (BMI) was calculated as  $\text{kg/m}^2$ . Waist circumference (centimetres) was measured in the standing position midway between the lower rib margin and the iliac crest. Supine blood pressure (mm Hg) was measured once after 10 minutes rest using a three-cuff manometer.

Ultrasound examination of right carotid artery was performed by specially trained and certified sonographers. The examination has been described in detail previously<sup>108</sup>. In short, the carotid bifurcation was scrutinised for the existence of atherosclerotic plaque, defined as a focal thickening of the intima-media layer. Intima media thickness (IMT) was determined in the far wall of the distal common carotid artery (IMT-cca) and in carotid bifurcation (IMT-bulb), according to the leading edge principal and using a specially designed computer-assisted image analysis system<sup>108, 110</sup>. Plaque occurrence was defined as a focal thickening of intima-media wall more than 1.25 mm<sup>111</sup>. Plaque score (values of 0, 1 or 2) was constructed in which 0 corresponded to no visual plaque, 1 corresponded to a visual plaque less than 10 mm<sup>2</sup>, and 2 corresponded to a plaque equal or greater than 10 mm<sup>2</sup><sup>111</sup>.

### *Information obtained from the self-administered questionnaire*

**Smoking habits;** classified as current smoker, ex-smoker and never smoker.

**Education;** classified into three groups:  $\leq 9$  years of education, 9 to 12 years of education, or more than 12 years of formal education. In some analyses, a 2-grade scale was used for classifying education which included 10 years or less, or more than 10 years of education.

**Physical activity;** calculated from questions adapted from the Minnesota Leisure Time Physical Activity Questionnaire including 18 different physical activities, separately for the four seasons. The number of minutes per week of each activity was multiplied with an intensity coefficient <sup>112</sup>. Low level of physical activity was defined as the lowest quartile of the score revealed by this questionnaire.

**Alcohol consumption;** was based on a menu-book in which the subjects filled in their meals and drinks for seven consecutive days. High alcohol consumption was characterized as consumption more than 30g alcohol per day for women and more than 40g alcohol per day for men <sup>113</sup>.

**Hypertension;** was defined as self-reported physician-diagnosed or current hypertensive treatment (paper I), in paper II to IV, hypertension included those subjects with a blood pressure  $\geq 140$  mm Hg systolic or  $\geq 90$  mm Hg diastolic <sup>114</sup>.

**Diabetes mellitus;** was defined as self-reported physician-diagnosed or current diabetic treatment (paper I). In paper II to IV, diabetes mellitus included subjects with fasting whole blood glucose equal or above 6.1 mmol/L, self-reported physician diagnosed diabetes mellitus or current treatment with anti-diabetic drugs.

## **Laboratory analyses**

All participants were instructed to refrain from smoking, alcohol and food intake, over night fasting or at least 10 hours before sample drawing. Blood samples were drawn for blood glucose (mmol/L), insulin (iu/L), HbA<sub>1</sub>C (%), triglycerides (mmol/L), total and HDL-cholesterol (mmol/L), and measured according to standard procedures at the Department of Clinical Chemistry, University Hospital Malmö <sup>115</sup>. The LDL cholesterol (mmol/L)

concentration was calculated according to Friedewald's formula<sup>116</sup>. Homeostasis model assessment (HOMA) value was calculated as (p-insulin x p-glucose)/22.5<sup>117</sup>.

The analysis of hsCRP (mg/L) was performed using the Tina-quant® CRP latex high sensitivity assay (Roche Diagnostics, Basel, Switzerland) on an ADVIA® 1650 Chemistry System (Bayer Healthcare, NY, USA). The principle of the assay is a particle-enhanced immunoturbidimetric assay, where anti-CRP antibody coated latex particles react with the CRP-antigen in the samples to form antigen/antibody complexes. The resulting agglutination can be measured turbidimetrically. Study samples were analysed as discrete samples and results were read in 6 second intervals for a 1 minute time period following 5 minutes incubation. The mean value of these measurements was the reported result. The assay was calibrated using C.f.a.s® protein (Roche Diagnostics, Basel Switzerland) within a two-point calibration curve and 5 quality control samples (Precipath®, Precinorm® both Roche Diagnostics, Basel, Switzerland; Assayed Human Sera Level 2 and Level 3, both Randox Laboratories, Crumlin, UK; pooled in-house human plasma) were used to monitor the performance of the assay. The average coefficient of variation was 4.6%.

## **Genetic analyses**

Deoxyribonucleic acid (DNA) was extracted from granulocyte or buffy coat suspensions, maintained at -80°C from the time of enrolment. Samples were thawed rapidly at 37°C; a 200 µL aliquot was subjected to QiaAmp mini-preps in 96-well format (Qiagen, Hilden, Germany) according to the manufacturers' instructions. SNPs were selected from the dbSNP database to include all non-synonymous coding SNPs with heterozygosity > 0.05. In addition, one promoter SNP (rs1421378), one SNP near the poly A attachment site of the 3' utr (rs974670) and one SNP far distal to this point (rs2216464) were selected to provide

haplotype information. In all, 2.5 ng DNA was used for each SNP assay on the Applied Biosystems 7900HT instrument using SNP genotyping assays C\_7582939\_10 for rs1421378 (5'A>G), C\_7582933\_10 for rs1805017 (R92H), C\_2032803\_1 for rs1805018 (I198T), C\_2032800\_20 for rs1051931 (A379V), C\_7582925\_10 for rs974670 (3'utr C>T) and C\_15858042\_10 for rs2216464 (far 3'T>C) and TaqMan Mastermix No UNG, in a total reaction volume of 6 µL in 384 microtiter plates, according to manufactures instructions.

### **Measurement of Lp-PLA<sub>2</sub> activity and mass**

Plasma aliquots prepared from fasted blood samples were collected and stored at -80°C. The mass of Lp-PLA<sub>2</sub> in the study samples was quantified using the PLAQ™ Test, i.e. a second-generation assay (diaDexus Inc., South San Francisco, CA, USA). The test resembles a sandwich enzyme immunoassay with two specific monoclonal antibodies as described by Caslake *et. al.*<sup>118</sup> combined with a horseradish-peroxidase – tetramethylbenzidine detection system. The change in absorbance resulting from the enzymatic turnover of the substrate was measured spectrophotometrically (Wallac, now Perkin Elmer Inc, Boston, MA, USA) and is directly proportional to the concentration of Lp-PLA<sub>2</sub> present in the study sample. A 6-point standard curve with known Lp-PLA<sub>2</sub> quantities, provided by the manufacturer, was employed to determine Lp-PLA<sub>2</sub> concentration of the study samples. All samples were analysed in duplicates and a duplicate was expected to show a coefficient of variation of less than 20% and if not the samples were reanalyzed. The average coefficient of variation was 4.26% on a random of 50 first subjects in the MDCS. The performance of the assay was monitored with two sets of three quality control samples, two provided by the manufacturer and one in-house quality control sample consisting of pooled plasma from four healthy donors. For an assay plate to be accepted, 4 out of the 6 quality control samples were expected to pass. Results

were calculated from the raw data, by point-to-point fit of the standard samples using Multicalc software (Wallac, now Perkin Elmer Inc, Boston, MA, USA).

Lp-PLA<sub>2</sub> activity was measured using [3H]PAF (platelet activating factor) as substrate. Briefly, plasma (5µL) or assay buffer (for determination of background and total dpm) were transferred into a 96 well flat-bottomed polystyrene plate (Costar) and allowed to equilibrate to room temperature. A 100µL aliquot of [3H]PAF substrate working solution (prepared fresh daily), consisting of 100µM [3H]PAF (0.4M [3H]PAF (Specific Activity 21.5 Ci/mmol, Perkin Elmer Life Sciences) plus 99.6M C16-PAF (Avanti Polar Lipids Inc) in assay buffer (100mM HEPES, 150mM NaCl, 5mM EDTA, pH7.4) was added to each well and the plate was vortexed and incubated at room temperature for 5 min. The reaction was terminated by addition of 50µL ice-cold aqueous bovine serum albumin solution (50mg/mL) followed by vortex mixing and incubation for 5min at 4C. Ice-cold trichloroacetic acid (56% aqueous solution; 25µL) was added to each well, vortexed and incubated for 15min at 4C. Plates were then sealed and centrifuged at ~6,000 x g for 15 min at 4°C, and aliquots of supernatant (45µL) were transferred to a picoplate (Perkin Elmer). In order to determine total dpm added, 10µL [3H]PAF substrate working solution was added to wells containing buffer instead of plasma. Some wells were left blank to determine background hydrolysis. Microscint-20 (200µL; Perkin Elmer Life Sciences) was added to all wells, plates were sealed and vortex mixed for 10 min. The plates were counted in a Topcount liquid scintillation counter (Perkin Elmer Life Sciences) and Lp-PLA<sub>2</sub> activity values (nmol PAF hydrolysed/min/mL) were derived from the raw data according to the formula below:

$$LpPLA2 \text{ activity} = 160 * (CPM_{45\mu L\text{-test}} - CPM_{Blanks}) / (CPM_{10\mu L\text{-spiking}} - CPM_{Blanks})$$

Where; *CPM<sub>45µL-test</sub>* is the mean dpm value for a test plasma

*CPM<sub>Blanks</sub>* is the mean dpm of wells without plasma of the blanks

*CPM<sub>10µL-spiking</sub>* is the mean dpm of wells containing [3H]PAF substrate

The range of detection was 8-150 nmol/min/mL. All samples were tested in duplicate. Samples were retested if the replicate coefficient of variation was >20%. The average coefficient of variation was 5.78%.

Plasma-EDTA samples are stable for Lp-PLA<sub>2</sub> activity and mass measurements within 7 days of collection for refrigerated samples and for more than 10 years from collection when stored at -70°C (data on file from diaDexus). All Lp-PLA<sub>2</sub> measurements were performed by diaDexus in San Francisco US in 2005.

### **Definition of the Metabolic Syndrome (MetS)**

The MetS was defined in accordance to the current NCEP/ATPIII criteria<sup>119, 120</sup>. Subjects who had three or more of the following criteria were considered to have MetS.

- Abdominal obesity: waist  $\geq$  102 cm for men and  $\geq$  88 cm for women
- Hypertriglyceridemia: triglyceride levels  $\geq$  1.70 mmol/L or, on drug treatment for elevated triglycerides.
- Low HDL-cholesterol levels: HDL  $<$  1.03 mmol/L for men and  $<$  1.30 mmol/L for women, or on drug treatment for decreased HDL.
- High blood pressure: Systolic blood pressure  $\geq$ 130 mmHg or diastolic blood pressure  $\geq$ 85 mmHg, or current treatment with blood pressure-lowering treatment.
- Elevated blood glucose: fasting whole blood glucose  $\geq$  5.6 to 6.0 mmol/L or established diabetes.

In paper III subjects with blood glucose  $>$ 6.1 mmol/L or established diabetes were excluded.

## **Classification of cardiovascular events**

Record linkage with the Swedish Hospital Discharge Register, the Malmö Myocardial Register <sup>121</sup>, the Stroke register of Malmö (STROMA) <sup>122, 123</sup>, and the Swedish Causes of Death Register. The ascertainment of cases and validity of these registries has been shown to be high <sup>124</sup>. The Swedish Hospital Discharge Register is a national register of all inpatients at all hospitals in Sweden since 1987, kept by the Centre for Epidemiology at the Swedish national Board of Health and Welfare <sup>124, 125</sup>. STROMA was established in 1989 with the purpose to monitor the incidence of stroke in Malmö <sup>123</sup>. Each case of suspected stroke, among both inpatients and outpatients, was assessed by a specialised research nurse, with supervision of a senior physician. Underlying causes of death and hospitalization diagnosis, respectively, were coded in accordance with the 9<sup>th</sup> version of the International Classification of Diseases (ICD-9). All subjects were followed from baseline examination until first occurring CHD, stroke, emigration from Sweden, or death until December 31<sup>st</sup> 2003. A CHD event was defined as non-fatal MI (ICD-code 410) or death due to ischemic heart disease (ICD-codes 410-414). Stroke was defined as fatal and non-fatal stroke (ICD-codes 430,431,434). Ischemic stroke (ICD-code 434) was diagnosed when computed tomography, magnetic resonance imaging or autopsy could verify the infarction and/or exclude haemorrhage and non-vascular disease. By definition subjects with transient ischemic attacks were not included. In order to find cases who moved out from the city after screening procedure, we also used the National Hospital Discharge Register and the Swedish Cause of Death Register, using the same diagnosis validation procedures as for STROMA.



## Statistics

All the statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) 11.0 in paper I, SPSS 13.0 in Paper II-III and SPSS 16.0 in paper IV.

Probability values less than 0.05 were considered statistically significant for non-interaction terms and  $P < 0.10$  was considered significant for interaction terms.

### Paper I

The distributions of triglycerides, glucose, insulin, HOMA, HbA1C, hsCRP and physical activity were markedly skewed and therefore log-transformed. Means with standard deviation (SD) [medians with inter quartile range for skewed variables] and percentages for baseline demographic and clinical characteristics were computed for the entire cohort and by sex. For continuous variables, we assessed correlation of Lp-PLA<sub>2</sub> with variables three ways with use of Pearson's or Spearman's correlation coefficient: partially adjusted for age and sex, partially adjusted for age, sex and LDL-cholesterol level, and partially adjusted for age, stratified by sex. Continuous factors were divided into tertiles and computed mean Lp-PLA<sub>2</sub> level within each tertile, stratified by sex. Mean Lp-PLA<sub>2</sub> level was computed and adjusted for age and sex by analysis of covariance for key categorical risk factors. Differences between categories were calculated and expressed with 95% confidence interval (CI). A general linear model was used to examine the incremental influence (cumulative R<sup>2</sup>) of risk factors for the degree of explanation of the variation in Lp-PLA<sub>2</sub>.

### Paper II

*T*-test for continuous variables and chi-square for dichotomous variables was used to test differences between subjects without or with incident CHD and ischemic stroke, respectively. Kaplan-Meier survival plots were used to study the cumulative event-free survival in relation

to tertiles of Lp-PLA<sub>2</sub>, a log-rank test was used to evaluate statistical differences between groups. Cox regression was used to investigate the incidence for CHD and ischemic stroke, respectively, in relation to tertiles (using the lowest tertile as referent) of Lp-PLA<sub>2</sub> activity and mass, respectively, with adjustment for confounding factors. Tolerance was calculated in order to assess collinearity between the independent variables. Possible interactions were analyzed by including interaction terms in the final model. To test if LDL-cholesterol levels modified the association between Lp-PLA<sub>2</sub> mass and CHD and ischemic stroke, we split the cohort by the median LDL- cholesterol level (i.e. 4.1 mmol/L).

### Paper III

Kappa statistics ( $\hat{\kappa}$ ) was used to assess the level of agreement between Lp-PLA<sub>2</sub> activity and mass (in tertiles). The incidence (per 1000 person-years) was standardized for sex and age (5-year groups) using direct standardization, and weighted for age-distribution of the present cohort. A general linear model was used to adjust the relations for age, sex, and LDL-cholesterol and to test the linear effects of Lp-PLA<sub>2</sub> levels across the number of components involved in the MetS. Age- and sex-adjusted c statistics, analogous to the area under the receiver operator characteristic (ROC) curve, were used to assess the discrimination of CVD prediction model based on high Lp-PLA<sub>2</sub> alone versus those having the MetS alone.

Kaplan-Meier survival analysis was used to assess the relation of Lp-PLA<sub>2</sub> activity and mass, respectively, and presence of MetS with CVD events during follow-up. Cox regression model was used to evaluate the potential additive effect of both elevated Lp-PLA<sub>2</sub> and presence of MetS association with incident CVD.

## Paper IV

Frequency differences and deviation from Hardy-Weinberg equilibrium were analyzed by CHI-2 test. For the genotype-Lp-PLA<sub>2</sub> plasma levels association analyses, we assumed an additive model of inheritance. *T*-test was used to compare mean plasma Lp-PLA<sub>2</sub> activity and mass, respectively, levels in different SNPs polymorphisms. A Spearman rho correlation test was used to assess degree of association between different SNPs. We conducted multiple linear regression analyses to test if genotypic effects on plasma levels of Lp-PLA<sub>2</sub> activity and mass, respectively, were independent of covariates. Three different models were used all with Lp-PLA<sub>2</sub> as the dependent variable. In addition, in model 2, an interaction term was included to assess possible interactions between sex and genotype on plasma levels of Lp-PLA<sub>2</sub>. Finally, highly correlated SNPs ( $r^2 > 0.5$ ) were simultaneously included in the model 2 to assess the independent contribution of each genotype on Lp-PLA<sub>2</sub> levels.

## Results and manuscript specific conclusion

### Paper I: The epidemiology of Lp-PLA<sub>2</sub>: Distribution and correlation with cardiovascular risk factors in a population-based cohort


#### Aim

To examine the cross-sectional associations of Lp-PLA<sub>2</sub> with anthropometric, demographic and other CV risk factors with plasma levels of Lp-PLA<sub>2</sub>.

#### Results

Mean (SD) Lp-PLA<sub>2</sub> activity was 45.5 (13.1) nmol/min/mL and mean Lp-PLA<sub>2</sub> mass was 269.8 (80.7) ng/mL. The correlation between Lp-PLA<sub>2</sub> activity and mass was  $r=0.57$  (Figure 1).


Figure 1. Correlation between Lp-PLA<sub>2</sub> activity and mass.  $n$ =number;  $r$ =correlation coefficient;  $p$ = $p$ -value



Lp-PLA<sub>2</sub> activity and mass were related to age, a correlation that was stronger in women than in men. Mean level of Lp-PLA<sub>2</sub> activity and mass, were significantly higher in men than in

women, 49.6 versus 42.5 nmol/min/mL, and 287.7 versus 257.2 ng/mL, respectively. Lp-PLA<sub>2</sub> was strongly correlated with total cholesterol, LDL, LDL/HDL ratio, HDL and triglycerides. Besides the lipids, the strongest associations in both genders to levels of Lp-PLA<sub>2</sub> were observed for fasting glucose, insulin and HOMA. In men, Lp-PLA<sub>2</sub> was also weakly associated with BMI and blood pressure. Lp-PLA<sub>2</sub> mass, but not Lp-PLA<sub>2</sub> activity, was weakly associated with hsCRP ( $r=0.10$  and  $r=0.02$ , respectively). Lp-PLA<sub>2</sub> increased with a greater extent of ultrasound-determined atherosclerosis, from 41 in the lowest tertile of IMT-cca to 42 and 44 nmol/min/mL in the second and third IMT-cca tertile, respectively (Figure 2).

Figure 2. Distribution of Lp-PLA<sub>2</sub> activity in different sub-groups.



Plack: a focal thickening of intima-media, more than 1.25mm, TG: triglycerides, IMT: intima-media thickening.

Current smokers, subjects with low educational level and subjects with presence of plaque in right carotid artery had statistically significant higher levels of Lp-PLA<sub>2</sub> activity compared to non-smokers, better educated subjects and subjects without plaques (Figure 2).

To assess how known CV risk factors explained the variability of Lp-PLA<sub>2</sub>, parameters were fit in a generalized linear model and the  $R^2$  was calculated. The 12 measured variables explained significantly more of the variation in Lp-PLA<sub>2</sub> activity than in Lp-PLA<sub>2</sub> mass (cumulative  $R^2=0.34$  versus  $R^2=0.19$ ). The strongest factors explaining the variation in the Lp-PLA<sub>2</sub> activity were LDL, HDL and sex. The corresponding factors for Lp-PLA<sub>2</sub> mass were LDL, sex, and smoking status. Seven percent of the variation in Lp-PLA<sub>2</sub> activity and 5% of the variation in Lp-PLA<sub>2</sub> mass was explained by gender.

## Conclusion

Plasma Lp-PLA<sub>2</sub> levels increases with age, and are higher in males and in smokers. Lp-PLA<sub>2</sub> is positively correlated with LDL-cholesterol and triglycerides and inversely correlated with HDL-cholesterol. Lp-PLA<sub>2</sub> mass, but not Lp-PLA<sub>2</sub> activity, is to a minor degree correlated with hsCRP. Both Lp-PLA<sub>2</sub> activity and mass are associated with carotid asymptomatic atherosclerosis (i.e. presence of plaques and CIMT). The variation of Lp-PLA<sub>2</sub> activity and mass was only explained to 35% and 19%, respectively, by measured variables.

**Paper II: Lp-PLA<sub>2</sub> activity and mass are associated with increased incidence of ischemic stroke. A population-based cohort study from Malmö, Sweden.**

**Aim**

To explore whether Lp-PLA<sub>2</sub> activity and mass, respectively, are associated with incidence of CHD and ischemic stroke, respectively.

**Results**

Subjects with incident ischemic stroke and CHD, respectively, had compared to event-free subjects significantly higher mean levels of blood pressure (142, 152 and 152 mmHg, respectively), Lp-PLA<sub>2</sub> activity (45.5, 49.9 and 50.7 nmol/min/mL, respectively) and Lp-PLA<sub>2</sub> mass (268.2, 290.4 and 291.6 ng/mL, respectively). Noticeable, subjects who experienced a CHD had compared to those with incident ischemic stroke and event-free subjects much higher LDL-cholesterol levels (4.4, 4.2 and 4.2 mmol/mL, respectively).

During a mean follow-up time of 10.6 years there were 347 incident CV events, 195 subjects had CHD of which 44 were fatal and 152 had an ischemic stroke of which 12 were fatal.

In an age- and sex-adjusted Cox regression model, the upper compared to the bottom tertile of both Lp-PLA<sub>2</sub> activity and mass, were statistically significantly related to an increased risk of ischemic stroke ( relative risk (RR); 1.79, 95% CI 1.16-2.76 and 1.71; 1.12-2.62, respectively). The corresponding figures for incident CHD were RR: 2.11; 95% CI 1.42-3.14 for Lp-PLA<sub>2</sub> activity and 1.34; 95% CI 0.94-1.90 for Lp-PLA<sub>2</sub> mass. The RR:s for ischemic stroke and CHD after further adjustment for potential confounders are presented in Table 1.

Table 1. Adjusted RR (95% CI) of first incident ischemic stroke or first CHD during 10 years follow-up by baseline Lp-PLA<sub>2</sub> activity and mass levels (in tertiles, T1-T3). Adjustment was made for age, sex LDL, HDL, use of lipid lowering treatment, BMI, hsCRP, smoking status, diabetes, SBP and high alcohol consumption.

	T1	T2	T3
<b>Lp-PLA<sub>2</sub> activity</b>			
Ischemic stroke	1.0 (ref)	1.44 (0.88-2.37)	1.94 (1.15-3.26)
CHD	1.0 (ref)	1.24 (0.79-1.96)	1.48 (0.92-2.37)
<b>Lp-PLA<sub>2</sub> mass</b>			
Ischemic stroke	1.0 (ref)	1.65 (1.02-2.65)	1.92 (1.20-3.10)
CHD	1.0 (ref)	0.84 (0.56-1.26)	0.95 (0.65-1.40)

## Conclusion

Elevated levels of LP-PLA<sub>2</sub> activity and mass, respectively, are associated with an increased risk of ischemic stroke, independent of other cardiovascular risk factors. No similar independent relationship was observed between Lp-PLA<sub>2</sub> and CHD.



**Paper III: Elevated Lp-PLA<sub>2</sub> levels add prognostic information to the Metabolic Syndrome on incidence of cardiovascular Events among middle-aged non-diabetic subjects.**

**Aim**

To study the relationship between Lp-PLA<sub>2</sub> and MetS, and to assess the independent contribution of MetS and Lp-PLA<sub>2</sub>, on incident CVD.

**Results**

In this non-diabetic cohort (n=4480) 16.4% (i.e.14.0% in women and 20.5% in men) had MetS. Subjects with MetS had significantly higher mean level of Lp-PLA<sub>2</sub> activity (51.3 versus 43.8 nmol/min/mL) and Lp-PLA<sub>2</sub> mass (280.9 versus 266.5 ng/mL) compared to subjects without MetS. Lp-PLA<sub>2</sub> is associated with all five metabolic components involved the syndrome. Both mean level of Lp-PLA<sub>2</sub> activity and mass, respectively, increased by increasing number of metabolic components (Table 3).

**TABLE 3. Mean Levels of Lp-PLA<sub>2</sub> Activity and Lp-PLA<sub>2</sub> Mass In Relation to No. of Components Involved in the Metabolic Syndrome (MetS)**

No. of MetS Components	No. of Subjects	Lp-PLA <sub>2</sub> Activity (nmol/min/mL)	Lp-PLA <sub>2</sub> Mass (ng/mL)
0	657	40.8±11.3	252.0±73.5
1	2082	43.5±11.8	266.3±77.6
2	1007	46.1±12.9	275.4±82.2
3	531	50.0±13.6	281.3±84.5
4 or 5	203	52.5±14.8†‡	276.9±85.5†‡


†P for trend <0.001, unadjusted. ‡P for trend <0.001 for activity and 0.472 for mass, respectively, after adjustment for age, sex, and LDL-cholesterol.

During mean follow-up time of 10.6 years a total of 261 incident CVD events occurred.

Elevated levels of Lp-PLA<sub>2</sub> activity was statistically significantly associated with incident CVD (RR; 1.46: 95% CI 1.01-2.13) in a multivariate adjusted model including MetS. Both elevated levels of Lp-PLA<sub>2</sub> and presence of MetS were, independently of traditional CV, risk

factors, associated with incident CVD. To evaluate the potential additive effect of both markers we divided the cohort in four groups, i.e. low to mid (tertile 1 and 2) versus high Lp-PLA<sub>2</sub> activity in combination with and without MetS. The referent group consisted of subjects with low to mid Lp-PLA<sub>2</sub> activity and no MetS. The RR for incident CVD associated with a combination of both elevated Lp-PLA<sub>2</sub> activity and MetS was, after adjustment for age, sex, LDL-cholesterol, lipid lowering treatment, smoking, hsCRP, physical activity and high alcohol consumption 1.97; 95% CI 1.34-2.90. Corresponding RR:s for high Lp-PLA<sub>2</sub> activity alone and for the presence of MetS alone were 1.40; 95% CI 1.03-1.92 and 1.46; 0.94-2.27, respectively.

Figure 2. Kaplan-Meier curves showing the incidence of first CVD events (MI or ischemic stroke) in relation to absence or presence of high Lp-PLA<sub>2</sub> and MetS in non-diabetic middle-aged subjects.



## Conclusion

Lp-PLA<sub>2</sub> is associated with MetS. Elevated levels of Lp-PLA<sub>2</sub> activity were related to increased risk for incident CVD regardless of MetS. There is an additive effect of Lp-PLA<sub>2</sub> to MetS on future CVD risk, which may identify an especially high risk individual.

## **Paper IV: In a population-based cohort study, variations in the PLA2G7 gene are associated with Lp-PLA<sub>2</sub> activity and mass.**

### **Aim**

To assess the effect of genetic variation in PLA2G7 gene on plasma Lp-PLA<sub>2</sub> activity and mass concentration levels.

### **Results**

Allele frequencies ranged from 20-41%, except for I198T (5%). Subjects who possess the minor allele for rs1051931 (A379V) and rs2216464 (far3CT) had significantly higher plasma Lp-PLA<sub>2</sub> activity, with a mean difference of 3.2 nmol/min/mL; 95% CI: 1.3-5.1,  $p < 0.001$  and 3.3; 1.4-5.2 nmol/min/mL,  $p < 0.001$ , respectively (Figure 2a). Lp-PLA<sub>2</sub> mass plasma levels were 32.2 (23.0-41.3,  $p < 0.001$ ) ng/mL and 17.9 (10.9-24.9,  $p < 0.001$ ) ng/mL that was significantly higher in subjects who possess the minor alleles for SNPs rs1805017 (R92H) and rs1421378 (5' AG) compared to subjects homozygous for the major alleles, respectively (Figure 2b). These associations remained statistically significant after taking age, HDL-, LDL-cholesterol and lipid lowering medication into account. Highly correlated SNPs were rs1051931 with rs2216464 ( $r^2 = 0.55$ ) and rs1805017 with rs1421378 ( $r^2 = 0.98$ ). Including both rs1805017 and rs1421378 simultaneously into the multivariate model, the association between Lp-PLA<sub>2</sub> mass and rs1805017 was strengthened, and the association between Lp-PLA<sub>2</sub> mass and rs1421378 turned inverse and non-statistically significant.

A sex-specific association between rs1051931 (i.e. A379V) and Lp-PLA<sub>2</sub> mass was observed ( $p$  for interaction 0.04), showing opposite relationships of Lp-PLA<sub>2</sub> mass levels and this polymorphism in men compared to women.

Figure 2a





Figure 2b



## Conclusion

In middle-aged Caucasians, genetic variation at the PLA2G7 gene locus significantly influences plasma Lp-PLA<sub>2</sub> activity and mass levels, in a position and sex-specific manner.

Identification of the biological effects of specific genetic variants may further increase their future value as biomarkers and potential therapeutic targets.

## General Discussion

There is global public health problem with an aging population, increasing number of individual's with obesity and MetS, and a remaining high incidence of CVD<sup>13, 89, 90</sup>. Some author argue that there is a need for a more intensive risk stratification in intermediate- and high risk patients to improve treatment for CVD, i.e. coronary events and stroke<sup>44</sup>. It has also been suggested that Lp-PLA<sub>2</sub> could be a novel biomarker, which represent a non-invasive tool to assess plaque stability<sup>62, 65</sup>. Accurate classifications of patients with atherosclerotic vascular disease is an important task in order to choose appropriate risk reducing therapy, which includes lifestyle modification and anti-hypertensive and lipid-lowering treatment<sup>126</sup>. It is widely recommended to use established current guidelines to help professionals to identify patients in order to reduce the occurrence of CHD, stroke and peripheral artery disease and their complications<sup>127-129</sup>. At present, inflammatory markers are not recommended for use in low-risk populations as a screening tool. Lp-PLA<sub>2</sub> is however suggested to be used in subjects to be at moderate or high risk by risk assessment<sup>126</sup>.

### **Lp-PLA<sub>2</sub>: correlation with other cardiovascular risk factors**

*Lp-PLA<sub>2</sub> is higher among men than women*

The finding that both Lp-PLA<sub>2</sub> activity and mass levels are higher in males compared to women (Paper 1) has been a consistent finding in other population-based and clinical studies<sup>70-72, 130</sup>. In the ARIC study the mean plasma levels of Lp-PLA<sub>2</sub> mass were 421µg/L in men and 339 µg/L in women<sup>70</sup>. In the Rotterdam study (which included assessment of Lp-PLA<sub>2</sub> activity) men had significantly higher levels than women, i.e. 46.8 compared to 43.0 nmol/min/mL<sup>72</sup>. Similar findings have also been reported from two other recently published

studies<sup>130, 131</sup>. The Dallas Heart Study; which included a multiethnic population, Lp-PLA<sub>2</sub> activity was reported to be higher in men compared to women, 161 versus 134 nmol/min/mL<sup>130</sup>. The US population-based Cardiovascular Health Study, including individuals aged 65 or older, also showed higher Lp-PLA<sub>2</sub> activity levels for men compared to women 42.7 vs 37.3 nmol/min/mL<sup>131</sup>. Although Lp-PLA<sub>2</sub> mass was measured in these studies no sex-specific data of Lp-PLA<sub>2</sub> mass has been currently reported. There is evidence that estrogen down-regulates Lp-PLA<sub>2</sub> expression<sup>132</sup>. In our study, users (i.e. 14%) compared to non-users of hormone replacement therapy (HRT) at baseline had lower levels of both Lp-PLA<sub>2</sub> activity and mass, i.e. 40.5 vs 43.0 nmol/min/mL and 248.4 vs 259.1 ng/mL, respectively. This finding is in accordance with the Women Health Study (WHS)<sup>69</sup> and the Dallas Heart Study<sup>130</sup>. In both studies levels of Lp-PLA<sub>2</sub> mass and Lp-PLA<sub>2</sub> activity, respectively, was significantly lower in HRT users compared to non-users (0.98 vs 1.23 mg/L and 126 vs 136 nmol/min/mL, respectively). However, excluding current HRT users in our cohort, the significant sex-specific difference in mean Lp-PLA<sub>2</sub> levels (as measured by mass or activity) remained. Further, research on the sex-specific difference in plasma Lp-PLA<sub>2</sub> is warranted to better understand the different physiological regulation of Lp-PLA<sub>2</sub> in men and women.

#### *Lp-PLA<sub>2</sub> is highly correlated with blood lipids but not with hsCRP*

A consistent finding, and in accordance with other studies, is that both Lp-PLA<sub>2</sub> activity and mass are strongly associated to blood lipids<sup>68-70, 118, 130, 131, 133, 134</sup>. This is not a surprising finding as Lp-PLA<sub>2</sub> is mainly bound to LDL particles<sup>118</sup>. In the present study almost 25% of the variation in both Lp-PLA<sub>2</sub> mass and activity could be explained by the variation of LDL-cholesterol. Furthermore, we found a significant but modest inverse correlation to HDL-cholesterol (Paper 1), a finding consisted with many<sup>69, 70, 130</sup> but not in all other studies<sup>68, 71</sup>.

The inverse correlation between Lp-PLA<sub>2</sub> and HDL-cholesterol in our study was stronger for Lp-PLA<sub>2</sub> activity than for mass ( $r=-0.24$  and  $r=-0.09$ , respectively). Differences between studies, however, could be explained by different design, study populations and methods.

Most studies, supporting our findings, have reported a non-significant correlation between Lp-PLA<sub>2</sub>, assessed as mass or activity, and hsCRP<sup>68, 70-72, 131</sup>. To our knowledge there are today only few studies reporting a significant however modest association between Lp-PLA<sub>2</sub> and hsCRP<sup>130, 135</sup>. One study included patients with established T1DM ( $n=92$ ) and in another study the association between hsCRP and Lp-PLA<sub>2</sub> mass was found only in women. The inflammatory marker hsCRP has been demonstrated as an independent predictor for incident CVD in many clinical and population-based studies<sup>42, 43, 136, 137</sup>. Numerous other studies have also demonstrated that Lp-PLA<sub>2</sub> is independently, including hsCRP, associated with incidence of CAD and stroke<sup>68, 70, 72, 138</sup>. This finding indicates that these two biomarkers may reflect distinctively different mechanisms on the atherosclerotic process. There are also some studies which have explored the additive effect of Lp-PLA<sub>2</sub> to hsCRP in predicting CHD and stroke<sup>70, 71, 139</sup>. All these studies have clearly demonstrated that the combination of elevated levels of hsCRP and Lp-PLA<sub>2</sub> was associated with a substantially increased risk of CHD or stroke. In addition in the HELICOR study, which included 312 patients with CAD and 479 age- and sex-matched controls, the correlation between Lp-PLA<sub>2</sub> mass and more than 15 different inflammatory and haemostatic markers was assessed<sup>134</sup>. In that study the top versus the bottom quartile of Lp-PLA<sub>2</sub> concentration was associated with an almost two-fold OR for severe angiographic CAD, which was independent of many inflammatory and hemostatic markers, i.e. hsCRP, serum amyloid A, plasminogen-activator-inhibitor-1, interleukin-6, tumor necrosis factor- $\alpha$ , intercellular adhesion molecule-1, white blood cell count, fibrinogen, D-dimer and lipoprotein(a). Together these results, including ours, supports Lp-



PLA<sub>2</sub> as a novel specific vascular inflammatory biomarker for CAD and ischemic stroke risk which is independent of other biomarkers reflecting systemic inflammation and haemostasis.

### *Lp-PLA<sub>2</sub> and endothelial dysfunction*

In symptomatic compared to asymptomatic carotid artery plaques increased levels of Lp-PLA<sub>2</sub> and lyso-PC have been found <sup>46</sup>. In a study by Lavi et al. it was demonstrated that the local production of Lp-PLA<sub>2</sub> and lyso-PC, which correlated with endothelial dysfunction, was higher in patients with early coronary atherosclerosis compared to healthy control subjects <sup>62</sup>. In our cross-sectional study we have showed that plasma Lp-PLA<sub>2</sub> activity levels increased with a greater extent of carotid ultrasound-determined atherosclerosis, i.e. IMT-cca, and Lp-PLA<sub>2</sub> was also associated with the amount of plaque (Paper 1). The association between Lp-PLA<sub>2</sub> and carotid IMT and plaque was however modest, and one possible explanation could be that this non-invasive imaging technique does not separate vulnerable from stable plaques. It is also been shown that Lp-PLA<sub>2</sub> staining is intense in rupture-prone plaques, however minimal staining was detected in early stable plaques <sup>65</sup>. In that study Lp-PLA<sub>2</sub> also co-localized with apoptotic macrophages. This finding suggests that Lp-PLA<sub>2</sub> may be closely linked with the progression and vulnerability of human coronary atheroma <sup>65</sup>. Coronary events do not occur only from severe luminal narrowing. Many acute CHD events seem to occur from atheroma showing less than 50% occlusion <sup>65, 140</sup>. This circumstance has shifted our focus of atherosclerosis as a focal disease caused by severe stenosis to a systemic disease characterized by endothelial dysfunction and plaque inflammation, and its consequence cardiovascular events by plaque rupture and thrombosis mainly at the sites of mild to moderate stenosis. Thus, some authors have even argued that inflammatory biomarker, as the

vascular specific Lp-PLA<sub>2</sub> enzyme should be included in current risk stratification models in order to better identify risk patients with unstable plaques<sup>23, 46, 65</sup>.

#### *Correlation between Lp-PLA<sub>2</sub> activity and mass*

The correlation between levels of Lp-PLA<sub>2</sub> activity and mass in the MDCS was rather high  $r=0.57$  (Paper 1). Only few clinical studies, and some population-based studies, have reported correlation between Lp-PLA<sub>2</sub> activity and mass. In summary, the reported correlation between activity and mass in these studies varies between  $r=0.35$  to  $r=0.86$ . In a small case-control study of male patients with CAD, the correlation was reported to be very high ( $r=0.86$ )<sup>118</sup>. In the PROVE IT- TIMI 22 study, a clinical trial involving patients with recent acute coronary syndrome (n=3625 and mostly men), there was only a modest correlation between Lp-PLA<sub>2</sub> activity and mass ( $r=0.35$ )<sup>138</sup>. In another study of patients with CHD, the correlation between Lp-PLA<sub>2</sub> activity and mass was  $r=0.57$ <sup>76</sup>. Similar or even higher correlations between Lp-PLA<sub>2</sub> activity and mass have been demonstrated from population-based studies including asymptomatic subjects<sup>130, 131</sup>. In the Dallas Heart Study<sup>130</sup>, there was a strong correlation ( $r=0.69$ ) between Lp-PLA<sub>2</sub> activity and mass, and in the Cardiovascular Health Study<sup>131</sup> the corresponding correlation coefficient was 0.51. The difference in association between Lp-PLA<sub>2</sub> activity and mass in different studies could have several explanations, i.e. differences in design, study populations or methods for measuring Lp-PLA<sub>2</sub>. Many present studies have used different Lp-PLA<sub>2</sub> assays. The Malmö, PROVE IT-TIMI 22, and Cardiovascular Health studies have all used a radiometric method to assess Lp-PLA<sub>2</sub> activity, while a calorimetric method was used in the Dallas Heart Study. To our knowledge no study has reported data on agreement between these two methods assessing Lp-PLA<sub>2</sub> activity within the same population. A first generation PLAC<sup>TM</sup> Test by diaDexus was initially used to measure Lp-

PLA<sub>2</sub> mass concentration in some studies at the beginning of year 2000. A second-generation diaDexus PLAC<sup>TM</sup> Test has been used in many other studies including the MDCS. Data from the AIRGENE study have demonstrated considerable stability and good reproducibility of serial Lp-PLA<sub>2</sub> mass measurements using this second-generation PLAC<sup>TM</sup> Test <sup>48</sup>.

*Variations in plasma levels of Lp-PLA<sub>2</sub> activity and mass, are modestly explained by other measured cardiovascular risk factors*

Variation in Lp-PLA<sub>2</sub> activity and mass levels, respectively, was in our study explained by measured lifestyle and biological variables only to 35% and 19%, respectively (Paper 1). This finding regarding Lp-PLA<sub>2</sub> activity is in agreement with a recent publication from the Cardiovascular Health Study <sup>131</sup>. In that study, including subjects >65 years, the total percentage variability (i.e. 29%) of Lp-PLA<sub>2</sub> activity was explained by age, gender, race, smoking, diabetes, blood pressure, blood lipids, BMI, CRP, creatinine, haemoglobin, platelets, fibrinogen, factor VII, white blood cell count and albumin. Furthermore, similar to our study LDL- and HDL-cholesterol were substantially the most important factors when explaining the Lp-PLA<sub>2</sub> activity variability. No other study, except MDCS, has to our knowledge examined factors accounting for the variability of Lp-PLA<sub>2</sub> mass. More studies are needed to further explore the remaining variability in terms of genetic determinants and the fact that Lp-PLA<sub>2</sub> expression has been shown to be dependent on leukocyte activation and is particularly high within the lipid core of the atheroma <sup>56, 65</sup>.

## **Association between Lp-PLA<sub>2</sub> and cardiovascular events**

*Lp-PLA<sub>2</sub> activity and mass are associated with increased incidence of ischemic stroke*

In Paper II it was concluded that elevated levels of Lp-PLA<sub>2</sub> activity and mass, respectively, was associated with increased incident of ischemic stroke. To our knowledge, the present study is the first prospective population-based cohort study exploring simultaneously Lp-PLA<sub>2</sub> activity and mass and their independent relationship to incident CHD and ischemic stroke. We found an age- and sex adjusted relationship between Lp-PLA<sub>2</sub> activity and risk of incident CHD. This was however attenuated and did not remain statistically significant when blood lipids were included into the model. No association was observed between Lp-PLA<sub>2</sub> mass and incident CHD. Many primary-<sup>68, 70, 72, 141</sup> as well as secondary-based<sup>74, 133, 138</sup> prevention studies have demonstrated a significant positive association between Lp-PLA<sub>2</sub> levels, measured as activity or mass, with incident CHD. However, in the ARIC study<sup>70</sup>, including almost 13,000 healthy middle-aged subjects with a follow-up period of 6 years, the association between Lp-PLA<sub>2</sub> and incidence of CHD (i.e. non-fatal and fatal MI) was, after taking traditional cardiovascular risk factors and hsCRP into account, observed only in subjects with an LDL-cholesterol below 130 mg/dL (i.e. 3.37 mmol/L). In the WHS (a rather small case-control study) which included only healthy middle-aged women, the univariate significant association between Lp-PLA<sub>2</sub> mass and incident CHD was attenuated and became non-statistically significant when adjustment for blood lipids was included in a multivariate analysis<sup>69</sup>. Furthermore, in the Veterans Affairs Trial (VA-HIT), an intervention trial with gemfibrozil treatment or placebo in almost 1500 post-MI men with low HDL-cholesterol and low LDL-cholesterol, Lp-PLA<sub>2</sub> activity has been found to be associated with incident coronary events (CE) but not with incident stroke<sup>142</sup>. As previously mentioned, this converse finding could be due to different study design, i.e. case-control, nested case-control or total population-based cohort, study populations including differences in mean levels of blood

lipids, and different methods and assay to measure Lp-PLA<sub>2</sub>. One possible explanation for the different association between Lp-PLA<sub>2</sub> and incident CHD and ischemic stroke, respectively, then in our study might be related to the high mean LDL-cholesterol, or to the fact that total- and LDL cholesterol is not as strongly correlated to stroke as it is for CHD<sup>19,27</sup>. Furthermore, in our study Lp-PLA<sub>2</sub> activity was more strongly than Lp-PLA<sub>2</sub> mass related to incident CHD. One possible explanation could be that enzyme activity but not mass, is related to sdLDL particles<sup>93</sup>, secondly that sdLDL particles are more atherogenic than large buoyant LDL-cholesterol<sup>143,144</sup>.

Most studies are looking at a combined endpoint of CVD, in terms of CHD and stroke. Few studies have explored the relation between Lp-PLA<sub>2</sub> levels and the incidence of stroke. Our finding regarding a two-fold increased risk for incident ischemic stroke associated with elevated levels of Lp-PLA<sub>2</sub>, as measured as activity and mass, is consistent with three other population-based studies, i.e. the ARIC,<sup>139</sup> the Rotterdam Study<sup>72</sup> and a recently published study of postmenopausal women<sup>145</sup>. The ARIC study, a case-cohort study, including men and women with a mean age of 58 years and racially mixed, found that increased levels of Lp-PLA<sub>2</sub> mass, predicted stroke<sup>139</sup>. An increased level of Lp-PLA<sub>2</sub> activity was associated with incident stroke in the Rotterdam study including predominantly older women (mean age 69)<sup>72</sup>. The third study of 1,874 postmenopausal women, of whom 61% were non-users of hormone replacement therapy (HRT), increased levels of Lp-PLA<sub>2</sub> mass was in non-users related to increased risk of ischemic stroke<sup>145</sup>. No increased stroke risk was observed for elevated Lp-PLA<sub>2</sub> among HRT-users.

*Elevated levels of Lp-PLA<sub>2</sub> activity add prognostic information to the MetS on incidence of CVD*

To our best knowledge the MDC is the first study exploring the interaction between Lp-PLA<sub>2</sub> activity and mass, respectively, and MetS on incidence of CVD in a large population-based non-diabetic cohort (Paper III). All metabolic components constituting the syndrome, according to algorithms proposed by the NCEP/ATPIII<sup>119, 120</sup>, were related to Lp-PLA<sub>2</sub> but the association was stronger for activity than for mass. In addition, with increased number of components there was a significant increase in plasma Lp-PLA<sub>2</sub> levels. Some smaller studies have shown that Lp-PLA<sub>2</sub> activity is related to established diabetes, i.e. in T2DM and T1DM patients. In a cross-sectional study including 92 T1DM patients, of whom 77 met the criteria of MetS, patients with in comparison to without MetS had significantly higher plasma levels of Lp-PLA<sub>2</sub> mass<sup>135</sup>. Another finding in that study, and supporting ours, was that Lp-PLA<sub>2</sub> mass levels increased linearly by increased number of MetS components. Lp-PLA<sub>2</sub> activity has also been shown associated with T1DM in another study, which included 42 T1DM patients and 48 control subjects<sup>146</sup>. Furthermore, in a case-control study by Serban et al, including 50 T2DM patients, 50 patients with dyslipidemia, and 50 controls, Lp-PLA<sub>2</sub> activity levels was found significantly higher in diabetic and dyslipidemic patients, respectively, compared to the control subjects<sup>147</sup>. Our findings are also consistent with the report from the Intermountain Heart Collaborative Study<sup>148</sup>. That study included almost 1500 angiographically patients, of whom 67% had CAD and 42% MetS, all followed for 7.5 years. Lp-PLA<sub>2</sub> mass levels above the median was more predictive of angiographic CAD in patients with than without MetS, and a subset of patients with MetS and elevated levels of Lp-PLA<sub>2</sub> had higher risk for CHD death (odd ratio [OR]: 2.14) compared to those with only elevated Lp-PLA<sub>2</sub> levels and absence of MetS (OR: 1.64). Subjects with MetS have been shown to have a high degree of oxidative stress and inflammation<sup>91, 149</sup>. Adipose cells present in

visceral fat generate inflammatory cytokines, which in turn can trigger hepatic production of CRP, and an association between CRP and endothelial dysfunction has been demonstrated in various experimental settings<sup>150</sup>. The MetS is a constellation of low-grade inflammatory components, and MetS individuals are at an increased risk for T2DM and CVD<sup>120</sup>. Subjects with presence as compared to absence of MetS have been shown to have significantly higher levels of different inflammatory marker, e.g. hsCRP, tumor necrose factor-R1 and R2, interleukin-6, intercellular adhesion molecule, and fibrinogen, all important factors contributing to a significantly increased risk of CVD<sup>42, 92, 149</sup>. However, the causality between hsCRP and components constituting the MetS has been questioned<sup>151</sup>. Furthermore, although hsCRP has been shown independent of MetS associated with incident CHD in many studies<sup>152-154</sup>, a recent report from the Nurses Health Study and the Health Professionals Study showed that most inflammatory markers did not add further information beyond MetS for prediction of CHD<sup>149</sup>.

In summary, firstly, as systemic inflammation markers, i.e. hsCRP, is not or only weakly related to Lp-PLA<sub>2</sub><sup>68, 70, 72, 130</sup>, and secondly Lp-PLA<sub>2</sub>, opposite to many other inflammatory markers, seems not or weakly to be unrelated to BMI or insulin resistance<sup>70, 94</sup>, together with our findings that elevated Lp-PLA<sub>2</sub> levels increases cardiovascular risk beyond the risk of having MetS in non-diabetic subjects, this together indicates a unique potential of Lp-PLA<sub>2</sub> as a vascular specific inflammatory marker. Thus, as subjects with MetS are considered to be at intermediate risk for CVD, some authors have even suggested that Lp-PLA<sub>2</sub> testing could presently be recommended as an adjunct to traditional risk assessment in patients at moderate and high 10-year risk of CVD<sup>126</sup>.

*Variations in PLA2G7 gene are associated with Lp-PLA<sub>2</sub> activity and mass.*

To our knowledge the MDCS is the first large study, including almost 4700 middle-aged Caucasians, exploring the association between *PLA2G7* gene polymorphisms and plasma levels of Lp-PLA<sub>2</sub> activity and mass, respectively. In Paper IV we found that VV (i.e. rs1051931) and CC (i.e. rs2216464) carriers, respectively, had significantly higher Lp-PLA<sub>2</sub> activity levels. Furthermore, we also found that subjects possessing the minor allele HH (i.e. rs1805017) and GG (i.e. rs141348) had significantly higher Lp-PLA<sub>2</sub> mass levels. At present there are only some smaller studies, or from selected patients or ethnic groups, who have reported information on the association between 379VV allele polymorphism and Lp-PLA<sub>2</sub> activity levels<sup>97, 101, 155</sup>. As ethnicity was the third most important predictor of Lp-PLA<sub>2</sub> variability in the Cardiovascular Health study, an analysis that included 18 lifestyle and biological factors<sup>131</sup>, together with the current knowledge that genetic influence may differ substantially between ethnic groups<sup>98, 99, 101</sup>, more studies are needed to further explore the clinically relevant impact of Lp-PLA<sub>2</sub> polymorphisms on plasma Lp-PLA<sub>2</sub> levels and future CVD risk.

## **Clinical implications**

Data from a large number of population-based, as well as primary and secondary preventive studies (Figure 1) confirm that Lp-PLA<sub>2</sub> is associated with an increased risk of incident CVD<sup>47</sup>. In addition, Lp-PLA<sub>2</sub> may represent a novel specific vascular inflammatory biomarker for CVD risk assessment. In contrast to many other inflammatory biomarkers (i.e. CRP), Lp-PLA<sub>2</sub> does not reflect systemic inflammation, and thus is not affected by common infections and arthritis<sup>49</sup>. As CVD is still the leading cause of death and disability in many countries<sup>13</sup>,



together with the fact that traditional CV risk factors only account for about 50-90% of variability of CVD risk<sup>9, 10, 156</sup>. Almost 6 out of 10 US patients with CAD have none or only one of conventional risk factor (i.e. hypertension, smoking, hypercholesterolemia and diabetes mellitus)<sup>8</sup>, and the shift in understanding that inflammation participates in atherosclerosis has emerged the need of inflammatory biomarkers in risk prediction and other applications including guide for therapy, etc<sup>9, 10</sup>. In a statement for healthcare professionals from the Centers for Disease Control and Prevention and American Heart Association the use of hsCRP has been already recommended as part of global risk prediction in asymptomatic individuals, particularly those considered to be at intermediate risk for CVD by traditional CV risk factors<sup>44</sup>. Whether the same recommendations is valid for Lp-PLA<sub>2</sub> remains to be elucidated, although the US Food and Drug Administration (FDA) recently has approved Lp-PLA<sub>2</sub> blood testing for assessing patients for risk of CHD and ischemic stroke. Worldwide, prevalence of MetS and obesity are increasing with an increasing number of subjects at intermediate to high CVD risk<sup>88-90</sup>. Some have already suggested that Lp-PLA<sub>2</sub>, which seems to be a reliable CVD predictor in studies across different ethnic populations<sup>47, 157</sup>, “is to be recommended as diagnostic test for vascular inflammation to better identify patients at high or very high risk who will benefit from intensification of lipid-modifying therapies”<sup>126</sup>. However, further clinical validation in well-designed observational and interventional studies is needed before these recommendations can be properly evaluated in order to include them in the clinical diagnostic algorithms.




Figure 1. A summary primary- and secondary preventive studies showing the association between elevated Lp-PLA<sub>2</sub> and incidence of CVD.

*What criteria are needed to determine the clinical significance of a risk marker/ factor?*

According to ATP III guidelines<sup>9</sup> an emerging risk factor should significantly, and independently of other major traditional risk factors, predict an increased risk. Secondly, there should be a relatively high prevalence of the risk factor in the general population. Third, the risk factor should be stable with respect to diet and diurnal variation. Fourth, it should be easy to measure, inexpensive and there should be an available well-standardized commercial assay. Finally, preferably modification of the risk factor should in a clinical trial be associated with a risk reduction.

Does Lp-PLA<sub>2</sub> meet all these criteria? There are over 25 prospective population-based studies showing consistently that elevated Lp-PLA<sub>2</sub> levels is significantly associated with an increased incidence of CVD, independently of other established major cardiovascular risk factors<sup>47</sup>. In recent meta-analysis by Garza et al., the authors concluded that Lp-PLA<sub>2</sub>, whether assessed as activity or mass, resulted in almost the same magnitude of risk (i.e. a two-fold) for incident CVD<sup>47</sup>. Lp-PLA<sub>2</sub> has a low biologic variability and fluctuation, which is similar to blood lipids<sup>48,49</sup>, which makes Lp-PLA<sub>2</sub> suitable to be assessed serially. Lp-PLA<sub>2</sub> levels could be measured both as activity or mass but there is no consensus today which of these is most valuable in a clinical setting. In our study, Lp-PLA<sub>2</sub> activity was, in comparison to mass, more strongly associated with presence of MetS and incident CVD. It has also been demonstrated that Lp-PLA<sub>2</sub> activity but not mass is associated with sdLDL<sup>93,158</sup>, a lipid fraction highly related to the MetS<sup>91,159</sup>. However, in paper III we also found that 40% of non-diabetic subject with high levels of Lp-PLA<sub>2</sub> activity also had low or medium levels of Lp-PLA<sub>2</sub> mass and vice versa. Furthermore, when interpreting different results from studies reporting Lp-PLA<sub>2</sub> mass it is of importance to know what generation of assay was used, i.e. so far mostly first and second generation of PLAC test from diaDexus. In fact, in a letter to the Editor of Clinical Chemistry, McConnell and Jaffe commented on the results from the AIRGENE study<sup>48</sup> and pointed out that second generation assays are no longer commercially available. They also suggested that the third in comparison to the second Lp-PLA<sub>2</sub> mass generation assay has much greater variability<sup>160</sup>. Recently, a fourth generation assay has been evaluated and cleared by US FDA. This assay is considered to be more easy to use in clinical practise; however there is yet no available information on validation or reproducibility for this forth-generation assay.

Several clinical studies have demonstrated the efficacy of lipid-lowering drug treatment (i.e. statins, fenofibrate, niacin, ezetimibe and omega-3 fatty acids) in association with reduction of Lp-PLA<sub>2</sub> plasma levels; this effect is mainly explained by a reduction in LDL-cholesterol<sup>68, 161-163</sup>. Whether modification of lifestyle factors in terms of smoking cessation, change of dietary habits, weight reduction and physical activity, etc, are related to reductions in Lp-PLA<sub>2</sub> levels remains to be evaluated. Today, there are several ongoing clinical trials evaluating the efficacy of Lp-PLA<sub>2</sub> inhibitors. One new compound under investigation (i.e. darapladib, SB-480848) has been shown to inhibit most of Lp-PLA<sub>2</sub> activity in atherosclerotic plaque from rabbits<sup>164</sup>. Oral administration of this compound to healthy volunteers has demonstrated a marked reduction in Lp-PLA<sub>2</sub> activity<sup>165, 166</sup>. Furthermore, recently the effect of darapladib on coronary plaque deformability composition and size was evaluated (using intravascular ultrasound imaging and palpography) in 330 patients with established CAD and with a follow-up of 12 months<sup>167</sup>. In contrast to placebo, and in addition to adherence to high-level of standard-care treatment, Lp-PLA<sub>2</sub> inhibition with darapladib prevented necrotic core expansion, a key determinant of plaque vulnerability. The authors suggested that Lp-PLA<sub>2</sub> inhibition may represent a novel therapeutic approach for CVD prevention. Future ongoing studies are underway to answer the question whether lowering Lp-PLA<sub>2</sub> levels by an inhibitor is associated with a reduced incidence of CVD.

## **Methodological aspects**

### *Representativity*

The participation rate in the MDCS was only 41% and it is common problem that attendance rate in cohort studies have declined during the last decades <sup>168</sup>. In a study of non-attendees in MDCS, the all-cause mortality was 2-3 times higher in non-participants compared to participants <sup>105</sup>. The increased mortality associated with non-participation could probably be explained by a higher prevalence of smoking, high alcohol consumption and poorer socio-economic circumstances among non-attendees as been demonstrated in previous population-based studies from Malmö <sup>168</sup>. Participants in the MDCS were recruited through community invitation. A previous study from the MDCS, which compared community against personal invitation showed favour in terms of socio-demographic and lifestyle factors for the community recruited approach <sup>104</sup>. Results from that study also strengthen the “healthy cohort” effect which could underestimate the results found for Lp-PLA<sub>2</sub> in the four studies included in this thesis.

### *Follow-up and Endpoints*

A common problem in long-term prospective studies is change of exposure over time. It is mostly unknown what happens between the baseline examination and during the follow-up period in terms of endpoints. In MDCS individuals with baseline-detected hypertension, T2DM, hyperlipedemia, etc, were referred to their private physician or to physicians within the primary health care organization in the city of Malmö. One can assume that many patients were subsequently initially and during the follow-up period treated for their detected CV risk factors which may consequently have reduced their forthcoming CVD risk. Furthermore, many moderate to high CVD risk MDCS subjects have also been involved in clinical trials <sup>169</sup>,

<sup>170</sup>, a circumstance that also might have changed their initial CV risk during the follow-up period. All these circumstances could influence the observed associations for Lp-PLA<sub>2</sub>, i.e. it is reasonable to assume that the observed risk increase for incident CVD, and in particular ischemic stroke, associated with elevated Lp-PLA<sub>2</sub> in MDCS might therefore be underestimated.

All individuals in MDCS were followed to first incident CHD, ischemic stroke or death or until 31 December 2003 by data linkage with regional and national registers. Several studies have documented the validity and completeness of these registers <sup>107, 121, 171</sup>. A validation study performed on the Swedish Hospital Discharge Register regarding the diagnosis MI found that an MI was false in only 5 percent of the cases <sup>124</sup>. A major strength of the stroke diagnosis is that STROMA register has continuously searched for patients with symptoms of stroke during the entire follow-up period and included both hospitalized and non-hospitalized patients. National registers were used to find those who moved away from the city. The diagnosis of stroke or subtype classification was verified by computed tomography scan, autopsy, or lumbar puncture and verified by a specialist research nurse under supervision of a senior physician. By definition, patients with transient ischemic attacks were excluded. Routine hospital discharge registries poorly reflect the incidence of stroke in the population, among patients discharged alive from hospital nearly 30 percent of the stroke diagnoses could be false-positive and 6 percent false-negative. A validation study from the Swedish Hospital Discharge Register on the diagnosis stroke has so far not been performed, but only 5% of all incident strokes in the MDCS occurred outside Malmö.

## Conclusions

Inflammation is today regarded as an important factor in the initiation and progression of atherosclerosis. Lp-PLA<sub>2</sub> as a novel biomarker of vascular inflammation may add information beyond traditional cardiovascular risk factors when predicting an individual's risk for CVD events.

This thesis shows that:

- In middle-aged Caucasians, genetic variation at the *PLA2G7* gene locus significantly influences plasma Lp-PLA<sub>2</sub> activity and mass levels, in a position and sex-specific manner.
- Plasma Lp-PLA<sub>2</sub> levels increases with age, and are higher in males and in smokers. Lp-PLA<sub>2</sub> is positively correlated with LDL-cholesterol and triglycerides and inversely correlated with HDL-cholesterol. Variation of Lp-PLA<sub>2</sub> activity and mass was only explained to 35% and 19%, respectively, by 12 measured lifestyle and biological variables.
- Our studies support previous evidence that high levels of LpPLA<sub>2</sub> activity and mass, respectively, independently of traditional CV risk including LDL-cholesterol and other blood lipids, increase the risk for incident CVD, especially for ischemic stroke.
- Lp-PLA<sub>2</sub> is associated with all components involved in the MetS according to NCEP/ATP III definition. Results from our study show that both Lp-PLA<sub>2</sub> and MetS are independently associated with incident CVD. Simultaneous presence of Lp-PLA<sub>2</sub> activity and MetS may identify an especially high risk individual.

## Populärvetenskaplig sammanfattning

Hjärtkärlsjukdom är fortfarande den vanligaste orsaken till för tidig död trots att insjuknandet under de senaste årtionden minskat och behandlingen blivit bättre. Befolkningen blir allt äldre, fler har övervikt/fetma, vilket medför att en ökande andel har metabola rubbningar. Metabola rubbningar och övervikt/fetma medför en ökad risk för hjärtinfarkt och stroke ("slaganfall"). Hjärtinfarkt är i västvärlden och Sverige den vanligaste, och stroke den tredje vanligaste, orsaken till för tidig död. Många av riskfaktorerna för hjärtkärlsjukdom som rökning, övervikt/fetma, fysisk inaktivitet, höga blodfetter, högt blodtryck och diabetes är livstilsrelaterade och därmed förändringsbara. Under de senaste decennierna har vissa av dessa riskfaktorer behandlats framgångsrikt. Rökningen har minskat, samt det finns idag effektiva mediciner som sänker blodtrycket och blodfetterna. Dessutom har vi ett bättre omhändertagande av bland annat diabetiker. Trots en intensiv behandling kvarstår hjärtkärlsjukdom fortfarande som den vanligaste dödsorsaken. I USA har populationsbaserade studier visat att mer än hälften av patienterna med etablerad kranskärlsjukdom har ingen eller endast en riskfaktor i termer av högt blodtryck, rökning, högt kolesterol eller diabetes. Dessutom är hjärtinfarkt eller plötslig hjärtdöd den första manifestationen av kranskärlsjukdom hos 6 av 10 män och 4 av 10 kvinnor. Många har ansett det behövs nya biomarkörer för att bättre kunna hitta de individer med hög risk att insjukna i hjärtkärlsjukdom och dess komplikationer. Hjärtkärlsjukdom är framför allt en aterosklerotisk ("åderförkalknings") åkomma med manifestationer, företrädesvis i stora kroppspulsådern, hals- ben- och hjärtats kranskärl, som utvecklas under lång tid utan några symtom. Viktiga komponenter i aterosklerosprocessen är åderförfattning och inflammation. Anrikningen av LDL-kolesterol ("farligt blodfett") som förhärdas ("oxideras") är grunden till det aterosklerotiska placket i kärlväggen. Olika inflammatoriska processer gör att placket kan bli instabilt vilket medför ökad risk för ruptur



och därmed komplikationer såsom akut hjärtinfarkt eller stroke. Under de senaste decennierna har flertalet populationsbaserade studier genomförts med avsikt att beskriva de inflammatoriska markörer förenade med hjärtkärlsjukdom. Ett antal inflammationsmarkörer, som t.ex. CRP ("snabbsänka") och speglade en systemisk inflammation, har oberoende av traditionella riskfaktorer visats vara relaterade till ökat insjuknande i hjärtkärlsjukdom. En annan biomarkör, dock mer specifikt kärlrelaterad, är Lp-PLA<sub>2</sub> (lipoprotein-associerat fosfolipas A<sub>2</sub>). Lp-PLA<sub>2</sub> är ett enzym i blodbanan som företrädesvis (ca 80 %) är bundet till LDL partikeln. Experimentella studier har visat att Lp-PLA<sub>2</sub> är involverade i kärlväggens aterosklerotiska process och finns i hög koncentration i det instabila plackett.

Syftet med detta avhandlingsarbete var att studera huruvida Lp-PLA<sub>2</sub>, mätt som aktivitet respektive massa, är och till vilken grad förenat med omgivnings-, livsstils- och andra biologiska riskfaktorer för hjärtkärlsjukdom (Delarbete 1). Dessutom utforska huruvida förhöjda nivåer av Lp-PLA<sub>2</sub> är förenat med en ökad risk för insjuknande i hjärtinfarkt och stroke (Delarbete 2). Vidare studera hur och om Lp-PLA<sub>2</sub> är associerat med faktorer som ingår i det metabola syndromet (anhopning av metabola riskfaktorer för hjärtkärlsjukdom) samt utvärdera om förhöjda nivåer av Lp-PLA<sub>2</sub> kan modifiera risken för hjärtkärlsjukdomsinsjuknande hos individer med syndromet (Delarbete 3). Avslutningsvis vill vi utforska om det finns genetiska polymorfier (genetiska varianter) som påverkar blodkoncentrationen och produktionen av Lp-PLA<sub>2</sub> aktivitet och massa (Delarbete 4).

För samtliga delarbeten användes deltagare i "Malmö Kost och Cancer" studiens hjärtkärlkohort, vilken består av 6103 män och kvinnor mellan 45-69 år. Samtliga individer undersöktes oblodigt med hjälp av ultraljud över halskärnen för förekomst och kvantifiering av ateroskleros. Fastande blodprov togs för analys av bland annat blodfetter, blodsocker samt

plasma och blodceller som lagrades. Lp-PLA<sub>2</sub> nivåer av aktivitet och massa i blodet analyserades på 5393 individer, vilket utgör studiepopulationen i denna avhandling. Delarbete 1 visade att Lp-PLA<sub>2</sub> är högre hos män jämfört med kvinnor samt att kvinnor med substitutionsbehandling med östrogen har ännu lägre nivåer. Plasma nivån av Lp-PLA<sub>2</sub> är högre hos rökare, högre hos individer med förhöjda blodfetter samt högre hos individer med plackförekomst i halspulsådern. Både Lp-PLA<sub>2</sub> aktivitet och massa är starkt relaterat till blodnivån av totalkolesterol och framför allt LDL, samt måttligt omvänt till HDL ("ofarligt"). Sambandet mellan Lp-PLA<sub>2</sub> nivån och ultraljudsdetekterad intima-media tjocklek ("indikerande ateroskleros") är svagt. Inget samband fanns mellan Lp-PLA<sub>2</sub> och den systemiska inflammationsmarkören CRP vilket indikerar olika patofysiologiska vägar av den inflammatoriska kaskaden i kärlväggen. Blodnivån av Lp-PLA<sub>2</sub> aktivitet och massa förklarades endast till 35 respektive 19 % av 12 studerade omgivnings-, livsstils- och biologiska variabler vilket antyder att Lp-PLA<sub>2</sub> har andra patofysiologiska mekanismer än traditionella riskfaktorer.

I delarbete II fann vi att individer med förhöjda nivåer av Lp-PLA<sub>2</sub> aktivitet eller massa i blodet har en fördubblad risk att insjukna i stroke. Riskökningen kvarstår även efter att man tagit hänsyn till effekten av andra riskfaktorer, såsom ålder, kön, rökning, blodfetter och blodtryck. Ett liknande samband kunde inte påvisas mellan förhöjda nivåer av Lp-PLA<sub>2</sub> aktivitet och massa och insjuknande i hjärtinfarkt

I samstämmighet med andra tidigare publikationer visade vi i delarbete III att individer med ett metabolt syndrom har en ökad risk för insjuknande i hjärtkärlsjukdom. Dessutom att Lp-PLA<sub>2</sub> nivån är starkt korrelerat till alla komponenter (høgt blodtryck, lågt HDL-kolesterol, høga triglycerider, bukfetma och rubbad sockertolerans) som ingår i syndromet. Vidare fann

via att ju fler metabola komponenter individen har desto högre är Lp-PLA<sub>2</sub> nivån. Studien visade även att förhöjda nivåer av Lp-PLA<sub>2</sub> aktivitet, oberoende av förekomsten av metabolt syndrom, var associerat med ökad risk för insjuknande i hjärtkärlsjukdom. Samtidig närvaro av metabolt syndrom och stegrade Lp-PLA<sub>2</sub> nivåer ökar risken ytterligare, vilket kan identifiera individer med en högre risk.

Genetikens betydelse för blodnivån av Lp-PLA<sub>2</sub> studerades i delarbete IV. I genen som kodar för Lp-PLA<sub>2</sub> (*PLA2G7*) finns det ett antal genetiska varianter beskrivna. I vårt arbete studerade vi sex olika varianter och deras effekt på plasma nivåer av Lp-PLA<sub>2</sub> aktivitet och massa. Homozygot (samma uppsättning ifrån båda föräldrarna) för två genetiska varianter (minor allele i A379V samt R92H) påverkade 7-12 % av nivån av Lp-PLA<sub>2</sub> i blodet

Då hjärtkärlsjukdom är den vanligaste dödsorsaken och de traditionella riskfaktorerna förklarar i olika populationer mellan 50-90 % av orsaken, är det av största vikt att vi hittar andra biomarkörer som kan identifiera fler individer med hög risk att insjukna i hjärtkärlsjukdom och dess komplikationer. Lp-PLA<sub>2</sub> kan vara en ny viktig biomarkör som indikerar lokal inflammation i kärlen.

Slutsatsen i denna avhandling är att flera faktorer, såväl genetiska som livsstilsfaktorer påverkar nivån av Lp-PLA<sub>2</sub> i blodet. Förhöjda nivåer av Lp-PLA<sub>2</sub> är associerat med en ökad risk för insjuknande i hjärtkärlsjukdom speciellt i stroke. Lp-PLA<sub>2</sub> adderar information om risk för framtida hjärtkärlinsjuknande hos individer med ett metabolt syndrom.

## Acknowledgements

I wish to thank and express my sincere gratitude to all who have helped me to complete and making this thesis possible.

First of all I would like to thank;

**Bo Hedblad**, Professor at the Department of Cardiovascular Epidemiology, my tutor and co-author throughout the work with my thesis. He has guided and taught me about epidemiology, and especially statistical approaches and analyses.

**Göran Berglund**, Professor at the Department of Medicine, my co-tutor and co-author in all papers. Göran introduced (or forced) me into the Lp-PLA<sub>2</sub> research field and I am grateful for his valuable inspiration, review and comments on my work.

**Jeanette “JJ” Nelson**, PhD at The Worldwide Epidemiology at GlaxoSmithKline in US, co-author in paper I-III, for good cooperation.

**Olle Melander MD, PhD**, and **Joyce Carlson, MD, PhD**, co-authors in paper IV, for providing expert help in the genetic field.

**Heide Stirnadel**, PhD at The Worldwide Epidemiology at GlaxoSmithKline in UK, for being co-author in paper IV.

**Gerd Östling**; for being a good friend, colleague, discussion partner, ultrasound expert, and finally for having the patience with me when I need to talk.

**Peter Nilsson**, Professor, for reading and commenting on my thesis and for being a good colleague.

**Gunnar Engström**, Professor, for valuable comments on my thesis and paper II-III.

**Ulf Lindblad**, Professor and **Anders Wallmark**, Ass. professor, for your contributions at my mid-seminar.

All my current and former colleagues at Clinical Research Unit, especially **Eva H, Kerstin S, Birgitta F, Kerstin N, Charlotte H, Annette G, Ulla L, Marita Å, Per L, Pierre Å, Carl B, Gun K, Anders D**, for all help, good social atmosphere, laughs and fine collaboration.

The studies were supported by grants from The Swedish Scientific Council, The Swedish Cancer Society, The Region of Skane, The Swedish Heart and Lung Foundation, and GlaxoSmithKline.

**Heart and Lung Foundation**, for their funding my visit to American Heart Association Congress and the PhD student grant.

**GlaxoSmithKline, Sweden**, for supporting my visit to European Society of Cardiology Congress, where I presented my accepted oral presentations and poster with results from this study.

**All subjects participating in the Malmö Diet and Cancer Study.**

At last but mostly I want to give all my heartily thanks to my family for their supporting in my work. Thanks to **Florence**, my mother for taking interest in my work and being a proud mother and grandmother. A specially thank to **Sven** my dear beloved husband who always trusted in me and supported me throughout the work with my thesis. Finally a hug to **Maria** and **Alexander**, for being our wonderful children.

## References

1. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2004 Chart Book on Cardiovascular, Lung, and Blood Diseases.: National Institutes of Health.; 2005.
2. International cardiovascular disease statistics: American Heart Association; 2005.
3. Statistics-Causes of Death, Causes of Death 2006. In: Welfare TNBoHa, ed.; 2008.
4. Braunwald E. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. *N Engl J Med.* 1997;337:1360-1369.
5. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. *Circulation.* 1999;100:1148-1150.
6. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. *Am J Med.* 2004;116 Suppl 6A:9S-16S.
7. Castelli WP. Lipids, risk factors and ischaemic heart disease. *Atherosclerosis.* 1996;124 Suppl:S1-9.
8. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. *Jama.* 2003;290:898-904.
9. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002;106:3143-3421.
10. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. *Clin Chem.* 2008;54:24-38.
11. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. *Lancet Neurol.* 2007;6:182-187.
12. Heron M. Deaths: leading causes for 2004. *Natl Vital Stat Rep.* 2007;56:1-95.
13. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation.* 2008;117:e25-146.
14. Zia E, Hedblad B, Pessah-Rasmussen H, Berglund G, Janzon L, Engstrom G. Blood pressure in relation to the incidence of cerebral infarction and intracerebral hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant. *Stroke.* 2007;38:2681-2685.
15. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med.* 1995;333:1301-1307.
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet.* 1994;344:1383-1389.
17. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med.* 1998;339:1349-1357.
18. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with

- atorvastatin in patients with stable coronary disease. *N Engl J Med.* 2005;352:1425-1435.
19. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet.* 2007;370:1829-1839.
  20. Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. *Am J Cardiol.* 2005;96:3K-13K; discussion 34K-35K.
  21. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med.* 2004;350:1495-1504.
  22. Murabito JM, Evans JC, Larson MG, Levy D. Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial coronary disease presentation. *Circulation.* 1993;88:2548-2555.
  23. Weintraub HS. Identifying the vulnerable patient with rupture-prone plaque. *Am J Cardiol.* 2008;101:3F-10F.
  24. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation.* 2006;113:e873-923.
  25. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. *Stroke.* 2003;34:623-631.
  26. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet.* 2003;361:1149-1158.
  27. Rodriguez BL, D'Agostino R, Abbott RD, Kagan A, Burchfiel CM, Yano K, Ross GW, Silbershatz H, Higgins MW, Popper J, Wolf PA, Curb JD. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factor effects. *Stroke.* 2002;33:230-236.
  28. Libby P, Sasiela W. Plaque stabilization: Can we turn theory into evidence? *Am J Cardiol.* 2006;98:26P-33P.
  29. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. *J Intern Med.* 2006;259:259-266.
  30. Hankey GJ. Potential new risk factors for ischemic stroke: what is their potential? *Stroke.* 2006;37:2181-2188.
  31. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med.* 2005;352:1685-1695.
  32. Ross R. Atherosclerosis--an inflammatory disease. *N Engl J Med.* 1999;340:115-126.
  33. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. *Nat Rev Immunol.* 2006;6:508-519.

34. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation*. 2002;105:1135-1143.
35. Wilson PW. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. *Circulation*. 2004;110:e568-571.
36. Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. *Nutr Rev*. 2007;65:S140-146.
37. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. *Circulation*. 2002;105:2632-2637.
38. Engstrom G, Stavenow L, Hedblad B, Lind P, Eriksson KF, Janzon L, Lindgarde F. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. *Diabetes*. 2003;52:442-447.
39. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med*. 2004;350:1387-1397.
40. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. *Arterioscler Thromb Vasc Biol*. 2007;27:15-26.
41. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. *Clin Chem*. 2001;47:403-411.
42. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. *Cardiol Clin*. 2003;21:315-325.
43. Hartford M, Wiklund O, Mattsson Hulten L, Persson A, Karlsson T, Herlitz J, Caidahl K. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. *J Intern Med*. 2007;262:526-536.
44. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Jr., Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*. 2003;107:499-511.
45. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. *Am J Cardiol*. 2008;101:41F-50F.
46. Mannheim D, Herrmann J, Versari D, Gossel M, Meyer FB, McConnell JP, Lerman LO, Lerman A. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. *Stroke*. 2008;39:1448-1455.
47. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. *Mayo Clin Proc*. 2007;82:159-165.
48. Khuseyinova N, Greven S, Ruckerl R, Trischler G, Loewel H, Peters A, Koenig W. Variability of serial lipoprotein-associated phospholipase A2 measurements in post myocardial infarction patients: results from the AIRGENE Study Center Augsburg. *Clin Chem*. 2008;54:124-130.
49. Wolfert RLK, N. W. Selby, R. G. Sarno, M. J. Warnick, R. G. Sudhir, K. . Biological variability and specificity of lipoprotein-associated phospholipase A2 (Lp-PLA2), a



- novel marker of cardiovascular risk. *Circulation*. 2004;2004;110(suppl 3):309:Circulation.
50. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M, Ikeda Y, Yamaguchi K. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. *Biochem Biophys Res Commun*. 1999;261:511-514.
  51. Macphee CH, Nelson J, Zalewski A. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. *Curr Opin Pharmacol*. 2006;6:154-161.
  52. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secrete platelet-activating factor acetylhydrolase. *J Biol Chem*. 1990;265:9682-9687.
  53. Macphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. *Curr Opin Pharmacol*. 2001;1:121-125.
  54. Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. *J Biol Chem*. 1999;274:7018-7024.
  55. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, Cariolou MA, Chapman MJ, Tselepis AD, Elisaf M. Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. *J Lipid Res*. 2002;43:256-263.
  56. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. *Arterioscler Thromb Vasc Biol*. 2005;25:923-931.
  57. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. *Faseb J*. 2001;15:2073-2084.
  58. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. *Biochem J*. 1999;338 ( Pt 2):479-487.
  59. Carpenter KL, Dennis IF, Challis IR, Osborn DP, Macphee CH, Leake DS, Arends MJ, Mitchinson MJ. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. *FEBS Lett*. 2001;505:357-363.
  60. Murugesan G, Sandhya Rani MR, Gerber CE, Mukhopadhyay C, Ransohoff RM, Chisolm GM, Kottke-Marchant K. Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines. *J Mol Cell Cardiol*. 2003;35:1375-1384.
  61. Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. *Atherosclerosis*. 2002;161:387-394.
  62. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. *Circulation*. 2007;115:2715-2721.

63. Sudhir K. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. *J Clin Endocrinol Metab.* 2005;90:3100-3105.
64. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. *Med Sci Monit.* 2006;12:RA5-16.
65. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2006.
66. Lavi S, Lavi R, McConnell JP, Lerman LO, Lerman A. Lipoprotein-associated phospholipase A(2) : review of its role as a marker and a potential participant in coronary endothelial dysfunction. *Mol Diagn Ther.* 2007;11:219-226.
67. Hakkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L, Rice SQ, Tew DG, Karkola K, Yla-Herttuala S. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. *Arterioscler Thromb Vasc Biol.* 1999;19:2909-2917.
68. Packard CJ, O'Reilly DS, Caslake MJ, McMahan AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. *N Engl J Med.* 2000;343:1148-1155.
69. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. *J Am Coll Cardiol.* 2001;38:1302-1306.
70. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. *Circulation.* 2004;109:837-842.
71. Koenig W, Khuseynova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. *Circulation.* 2004;110:1903-1908.
72. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. *Circulation.* 2005;111:570-575.
73. Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, Rihal CS, Lerman LO, Lerman A. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. *Arterioscler Thromb Vasc Biol.* 2006;26:106-111.
74. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. *Eur Heart J.* 2005;26:137-144.
75. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Bohm BO, Marz W. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and

- other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. *Circulation*. 2005;111:980-987.
76. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. *Arterioscler Thromb Vasc Biol*. 2006;26:1586-1593.
  77. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. *Clin Chem*. 2006;52:1331-1338.
  78. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. *Arch Intern Med*. 2006;166:2073-2080.
  79. Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. *Am J Med*. 2006;119:S3-9.
  80. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care*. 2001;24:683-689.
  81. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes*. 1988;37:1595-1607.
  82. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. *Diabetes*. 2004;53:1195-1200.
  83. Bloomgarden ZT. 2nd International Symposium on triglycerides and HDL: metabolic syndrome. *Diabetes Care*. 2005;28:2577-2584.
  84. Bloomgarden ZT. Definitions of the insulin resistance syndrome: the 1st World Congress on the Insulin Resistance Syndrome. *Diabetes Care*. 2004;27:824-830.
  85. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. *Circulation*. 2004;110:1251-1257.
  86. Qiao Q. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. *Diabetologia*. 2006;49:2837-2846.
  87. Nilsson PM, Engstrom G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects--a population-based study comparing three different definitions. *Diabet Med*. 2007;24:464-472.
  88. Menotti A, Lanti M, Kromhout D, Blackburn H, Nissinen A, Dontas A, Kafatos A, Nedeljkovic S, Adachi H. Forty-year coronary mortality trends and changes in major risk factors in the first 10 years of follow-up in the seven countries study. *Eur J Epidemiol*. 2007;22:747-754.
  89. Kolovou GD, Anagnostopoulou KK, Salpea KD, Mikhailidis DP. The prevalence of metabolic syndrome in various populations. *Am J Med Sci*. 2007;333:362-371.
  90. Grundy SM. Metabolic syndrome pandemic. *Arterioscler Thromb Vasc Biol*. 2008;28:629-636.
  91. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). *J Intern Med*. 2002;252:440-447.

92. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. *Circulation*. 2005;111:1448-1454.
93. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. *Clin Chem*. 2005;51:2264-2273.
94. McLaughlin TA, F. Wolfert, R. Lamendola, C. Reaven, G. Reaven, P. Lipoprotein-associated phospholipase A2 is not increased in association with insulin resistance.: *Arterioscler Thromb Vasc Biol*; 2004.
95. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet*. 2005;365:1415-1428.
96. Bell R, Collier DA, Rice SQ, Roberts GW, MacPhee CH, Kerwin RW, Price J, Gloger IS. Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis in schizophrenia. *Biochem Biophys Res Commun*. 1997;241:630-635.
97. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, Gao PS, Forster J, Kuehr J, Hopkin JM, Shirakawa T, Deichmann KA. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. *Am J Hum Genet*. 2000;66:1522-1530.
98. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, Imaizumi T, Takamatsu S, Zimmerman GA, McIntyre TM, Gray PW, Prescott SM. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. *J Clin Invest*. 1996;97:2784-2791.
99. Balta G, Gurgey A, Kudayarov DK, Tunc B, Altay C. Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. *Thromb Res*. 2001;101:231-234.
100. Abuzeid AM, Hawe E, Humphries SE, Talmud PJ. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. *Atherosclerosis*. 2003;168:283-288.
101. Ninio E, Tregouet D, Carrier JL, Stengel D, Bickel C, Perret C, Rupprecht HJ, Cambien F, Blankenberg S, Tiret L. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. *Hum Mol Genet*. 2004;13:1341-1351.
102. Liu PY, Li YH, Wu HL, Chao TH, Tsai LM, Lin LJ, Shi GY, Chen JH. Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction. *J Thromb Haemost*. 2006;4:1023-1028.
103. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. *J Intern Med*. 1993;233:45-51.
104. Manjer J, Elmstahl S, Janzon L, Berglund G. Invitation to a population-based cohort study: differences between subjects recruited using various strategies. *Scand J Public Health*. 2002;30:103-112.
105. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, Mattisson I, Berglund G. The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. *Eur J Cancer Prev*. 2001;10:489-499.
106. Rosvall M, Ostergren PO, Hedblad B, Isacson SO, Janzon L, Berglund G. Occupational status, educational level, and the prevalence of carotid atherosclerosis in

- a general population sample of middle-aged Swedish men and women: results from the Malmo Diet and Cancer Study. *Am J Epidemiol.* 2000;152:334-346.
107. Engstrom G, Berglund G, Goransson M, Hansen O, Hedblad B, Merlo J, Tyden P, Janzon L. Distribution and determinants of ischaemic heart disease in an urban population. A study from the myocardial infarction register in Malmo, Sweden. *J Intern Med.* 2000;247:588-596.
  108. Persson J, Formgren J, Israelsson B, Berglund G. Ultrasound-determined intima-media thickness and atherosclerosis. Direct and indirect validation. *Arterioscler Thromb.* 1994;14:261-264.
  109. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. *Diabet Med.* 2000;17:299-307.
  110. Wendelhag I, Gustavsson T, Suurkula M, Berglund G, Wikstrand J. Ultrasound measurement of wall thickness in the carotid artery: fundamental principles and description of a computerized analysing system. *Clin Physiol.* 1991;11:565-577.
  111. Rosvall M, Janzon L, Berglund G, Engstrom G, Hedblad B. Incident coronary events and case fatality in relation to common carotid intima-media thickness. *J Intern Med.* 2005;257:430-437.
  112. Mattisson I, Wirfalt E, Aronsson CA, Wallstrom P, Sonestedt E, Gullberg B, Berglund G. Misreporting of energy: prevalence, characteristics of misreporters and influence on observed risk estimates in the Malmo Diet and Cancer cohort. *Br J Nutr.* 2005;94:832-842.
  113. Mattisson I, Wirfalt E, Wallstrom P, Gullberg B, Olsson H, Berglund G. High fat and alcohol intakes are risk factors of postmenopausal breast cancer: a prospective study from the Malmo diet and cancer cohort. *Int J Cancer.* 2004;110:589-597.
  114. Li C, Engstrom G, Berglund G, Janzon L, Hedblad B. Incidence of Ischemic Stroke in Relation to Asymptomatic Carotid Artery Atherosclerosis in Subjects with Normal Blood Pressure. A Prospective Cohort Study. *Cerebrovasc Dis.* 2008;26:297-303.
  115. Nilsson-Ehle P GP-O. *Laurells klinisk kemi i praktisk medicin (in Swedish)*. Studentlitteratur; 2003.
  116. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* 1972;18:499-502.
  117. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia.* 1985;28:412-419.
  118. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. *Atherosclerosis.* 2000;150:413-419.
  119. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *Jama.* 2001;285:2486-2497.
  120. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr., Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation.* 2005;112:2735-2752.

121. Tyden P, Hansen O, Janzon L. Intra-urban variations in incidence and mortality in myocardial infarction. A study from the myocardial infarction register in the city of Malmo, Sweden. *Eur Heart J*. 1998;19:1795-1801.
122. Khan FA, Zia E, Janzon L, Engstrom G. Incidence of stroke and stroke subtypes in Malmo, Sweden, 1990-2000: marked differences between groups defined by birth country. *Stroke*. 2004;35:2054-2058.
123. Jerntorp P, Berglund G. Stroke registry in Malmo, Sweden. *Stroke*. 1992;23:357-361.
124. Evaluation of quality of diagnosis of acute myocardial infarction, inpatient register 1997 and 1995. In: Welfare TNBoHa, ed.: The National Board of Health and Welfare; 2000.
125. Myocardial infarctions in Sweden 1987-2000. In Swedish. In: Epidemiology TNBoHaWCo, ed.; 2003.
126. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, Lerman A, McConnell JP, Weintraub HS. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. *Am J Cardiol*. 2008;101:51F-57F.
127. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancina G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur Heart J*. 2003;24:1601-1610.
128. Mahoney LT, Burns TL, Stanford W, Thompson BH, Witt JD, Rost CA, Lauer RM. Usefulness of the Framingham risk score and body mass index to predict early coronary artery calcium in young adults (Muscatine Study). *Am J Cardiol*. 2001;88:509-515.
129. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998;97:1837-1847.
130. Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, de Lemos JA. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. *Atherosclerosis*. 2008;199:110-115.
131. Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, Psaty BM. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. *J Am Geriatr Soc*. 2008;56:792-799.
132. Miyaura S, Maki N, Byrd W, Johnston JM. The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma. *Lipids*. 1991;26:1015-1020.
133. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, Tiret L, Ninio E. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. *J Lipid Res*. 2003;44:1381-1386.
134. Khuseyinova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, Scharnagl H, Maerz W, Brenner H, Koenig W. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. *Atherosclerosis*. 2005;182:181-188.
135. Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. *J Diabetes Complications*. 2006;20:343-348.
136. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. *Circulation*. 2004;109:1349-1353.

137. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. *N Engl J Med.* 2004;351:2599-2610.
138. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. *Circulation.* 2006;113:1745-1752.
139. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. *Arch Intern Med.* 2005;165:2479-2484.
140. Falk E, Shah PK, Fuster V. Coronary plaque disruption. *Circulation.* 1995;92:657-671.
141. Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. *J Am Coll Cardiol.* 2008;51:913-919.
142. Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. *Arterioscler Thromb Vasc Biol.* 2008;28:1172-1178.
143. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. *Atherosclerosis.* 1994;106:241-253.
144. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. *Jama.* 1996;276:875-881.
145. Wassertheil-Smoller S, Kooperberg C, McGinn AP, Kaplan RC, Hsia J, Hendrix SL, Manson JE, Berger JS, Kuller LH, Allison MA, Baird AE. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. *Hypertension.* 2008;51:1115-1122.
146. de Castro SH, Faria Neto HC, Gomes MB. Platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with type 1 diabetes mellitus. *Arq Bras Cardiol.* 2007;88:179-184.
147. Serban M, Tanaseanu C, Kosaka T, Vidulescu C, Stoian I, Marta DS, Tanaseanu S, Moldoveanu E. Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus. *J Cell Mol Med.* 2002;6:643-647.
148. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. *Expert Rev Mol Diagn.* 2007;7:511-517.
149. Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, Rimm EB. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. *Atherosclerosis.* 2008;197:392-399.
150. Bisioendial RJ, Kastelein JJ, Stroes ES. C-reactive protein and atherogenesis: from fatty streak to clinical event. *Atherosclerosis.* 2007;195:e10-18.

151. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, Hattersley AT, Ebrahim S, Lowe GD, Rumley A, Davey Smith G. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. *Lancet*. 2005;366:1954-1959.
152. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. *Circulation*. 2003;107:391-397.
153. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. *Circulation*. 2003;108:414-419.
154. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. *Circulation*. 2004;110:380-385.
155. Wootton PT, Stephens JW, Hurel SJ, Durand H, Cooper J, Ninio E, Humphries SE, Talmud PJ. Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus. *Atherosclerosis*. 2006;189:149-156.
156. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004;364:937-952.
157. Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Koenig W, Sacco R, Elkind M, Talmud P, Rimm E, Cannon CP, Packard C, Barrett-Connor E, Hofman A, Kardys I, Wittteman JC, Criqui M, Corsetti JP, Rainwater DL, Moss AJ, Robins S, Bloomfield H, Collins D, Packard C, Wassertheil-Smoller S, Ridker P, Ballantyne C, Cannon CP, Cushman M, Danesh J, Gu D, Hofman A, Nelson JJ, Thompson S, Zalewski A, Zariffa N, Di Angelantonio E, Kaptoge S, Thompson A, Thompson S, Walker M, Watson S, Wood A. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. *Eur J Cardiovasc Prev Rehabil*. 2007;14:3-11.
158. Karabina SA, Liapikos TA, Grekas G, Goudevenos J, Tselepis AD. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. *Biochim Biophys Acta*. 1994;1213:34-38.
159. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. *Jama*. 1998;279:1955-1961.
160. McConnell JP, Jaffe AS. Variability of lipoprotein-associated phospholipase A2 measurements. *Clin Chem*. 2008;54:932-933.
161. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. *Arterioscler Thromb Vasc Biol*. 2002;22:306-311.
162. Winkler K, Abletshauer C, Friedrich I, Hoffmann MM, Wieland H, Marz W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2004;89:1153-1159.
163. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed



- dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. *J Am Coll Cardiol.* 2006;48:396-401.
164. Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. *Bioorg Med Chem Lett.* 2003;13:1067-1070.
165. Zalewski A, Macphee C, Nelson JJ. Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis. *Curr Drug Targets Cardiovasc Haematol Disord.* 2005;5:527-532.
166. Mohler ER, 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. *J Am Coll Cardiol.* 2008;51:1632-1641.
167. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. *Circulation.* 2008;118:1172-1182.
168. Janzon L, Hanson BS, Isacson SO, Lindell SE, Steen B. Factors influencing participation in health surveys. Results from prospective population study 'Men born in 1914' in Malmo, Sweden. *J Epidemiol Community Health.* 1986;40:174-177.
169. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). *Circulation.* 2001;103:1721-1726.
170. Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. *J Intern Med.* 2007;261:293-305.
171. Merlo J, Lindblad U, Pessah-Rasmussen H, Hedblad B, Rastam J, Isacson SO, Janzon L, Rastam L. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. *Eur J Epidemiol.* 2000;16:235-243.